PFIZER
PFENext catalyst
Rimegepant
Acute Migraine
Get an email about PFE's next catalysts
Track PFIZER (PFE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 47 more upcoming events in our data (Phase 2 readout, Phase 3 readout, trial start).See the timeline
48 upcoming, 5 past
Rimegepant Phase 3 Est. Readout
Primary completion for Rimegepant trial (NCT06641466) in Menstrual Migraine
Sourceelranatamab Phase 2 Est. Readout
Estimated primary completion for elranatamab trial (NCT06832865) in Relapsed Refractory Multiple Myeloma (RRMM). Topline data typically follows completion by weeks to months.
SourceRitlecitinib higher dose Phase 3 Est. Readout (B7981027)
Primary completion for Ritlecitinib higher dose trial (NCT07029828) in Severe Alopecia Areata
SourceSunitinib Phase 2 Est. Readout
Estimated primary completion for Sunitinib trial (NCT03297606) in Lymphoma, Non-Hodgkin. Topline data typically follows completion by weeks to months.
SourceVLA15 Phase 3 Est. Readout
Primary completion for VLA15 trial (NCT07500506) in Lyme Disease
SourceRitlecitinib Phase 2 Est. Readout
Primary completion for Ritlecitinib trial (NCT07228390) in Hidradenitis Suppurativa
Sourcedisitamab vedotin Phase 2 Est. Readout
Primary completion for disitamab vedotin trial (NCT04879329) in Urothelial Carcinoma
SourceTucatinib Oral Tablet Phase 2 Est. Readout (ETIC-LM)
Estimated primary completion for Tucatinib Oral Tablet trial (NCT05800275) in Leptomeningeal Metastasis. Topline data typically follows completion by weeks to months.
SourceHow PFE's past catalysts played out
Market Overview
Stock performance and key metrics
Pfizer Inc. (/ˈfaɪzər/ FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America.
WebsiteEpoetin Hospira
Chronic Renal Failure Requiring Hemodialysis
Remicade
Crohn's Disease
Enbrel (etanercept)
Ankylosing Spondylitis
Zmax
Otitis Media
Venlafaxine ER
Panic Disorder
Levonorgestrel and Ethinyl Estradiol
Oral Contraceptive
ARV-471
Advanced Breast Cancer
ARV-471 (PF-07850327)
Breast Cancer
heptavalent pneumococcal conjugate vaccine, Prevenar
Allogeneic Haematopoietic Stem Cell Transplantation
valdecoxib
Pain
Havrix (HAV)
Meningococcal Vaccine
NWP09
Attention Deficit Hyperactivity Disorder
PF-07220060
Liposarcoma
Diflucan IV, oral
Candidiasis
Rimegepant (PF-07899801)
Acute Treatment of Migraine
13 valent Pneumococcal Conjugate Vaccine
Pneumococcal Infections
7vPnc pneumococcal conjugate vaccine
Vaccines, Pneumococcal
Bifeprunox
Schizophrenia
CT-P13
Crohn's Disease
Sunitinib malate
Breast Neoplasms
Ethambutol hydrochloride
Mycobacterium Avium-intracellulare Infection
ritonavir
COVID-19
ReFacto AF
Hemophilia A
binimetinib
MSS
ropinirole
Parkinson Disease
Desvenlafaxine Succinate Sustained-Release
Major Depressive Disorder
Ceftazidime - Avibactam (CAZ-AVI)
Complicated Urinary Tract Infection
Etanercept
Pulmonary Fibrosis
Avelumab (MSB0010718C)
Renal Cell Cancer
Steroids
Kidney Failure
rFIX
Hemophilia B
In open-label phase: treatment with tofacitinib
Arthritis Juvenile Idiopathic
Ibuprofen ER
Pain
cefuroxime plus erythromycin
Pneumonia
PF-05280014
Metastatic Breast Cancer
Quillivant Oral Suspension XR
Attention Deficit Hyperactivity Disorder
Prevenar 13™
Infections, Meningococcal
Desvenlafaxine Succinate
Major Depressive Disorder
Enzalutamide
Breast Cancer
Voriconazole
Neutropenia
indobufen
Atrial Fibrillation
desvenlafaxine
Depressive Disorder, Major
Isovorin
Gastric Cancer
Nirmatrelvir
COVID-19
Doripenem
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Midazolam
Sedation
Artemether-lumefantrine
Malaria, Falciparum
Crizotinib
Non Small Cell Lung Cancer
Rapamune
Renal Allograft Recipients
Effexor XR
Depression
Fesoterodine PR
Urinary Bladder, Neurogenic
desipramine
Depression
procarbazine hydrochloride
Brain and Central Nervous System Tumors
desvenlafaxine succinate sustained release
Vasomotor Symptoms
Anidulafungin, VER002
Aspergillosis
treatment
Non Squamous Lung Cancer
Tofacitinib
Rheumatoid Arthritis
Etrasimod
Alopecia Areata
Elranatamab
Multiple Myeloma
Fenofibrate
Hyperlipidemia
Disease-modifying antirheumatic drug
Arthritis, Rheumatoid
20vPnC
Pneumococcal Disease
Genotonorm
Growth Disorders
Varenicline tartrate
Smoking Cessation
pegaptanib sodium
Macular Degeneration
rLP2086 vaccine
Meningitis, Meningococcal
Apixaban
Atrial Fibrillation
Talazoparib
Prostate Cancer
Fx-1006A
Familial Amyloid Polyneuropathy
Sulfadoxine-Pyrimethamine/Chloroquine
PLASMODIUM FALCIPARUM MALARIA
Mefloquine
Malaria, Falciparum
CP 690,550
Rheumatoid Arthritis
PN-152,243)/PN-196,444
Sarcoma
Physician's-Choice
Breast Neoplasms
Bazedoxifene Acetate
Osteoporosis
gemcitabine hydrochloride
Lung Cancer
Sigvotatug Vedotin
Non-Small Cell Lung Cancer
Epogen Amgen
Chronic Renal Failure
desvenlafaxine SR
Depression
PVC (daily, 7 days off)
Atrophic Vaginitis
Dexmedetomidine HCL Injection
Awake Fiberoptic Intubation
Bazedoxifene/Conjugated Estrogen
Vaginal Atrophy
desvenlafaxine succinate sustained release tablets
Major Depressive Disorder
Cyclosporine
Kidney Transplant
Amphotericin B
Mycoses
Pegvisomant
Acromegaly
Ceftaroline
Community-Acquired Bacterial Pneumonia
MenACWY-TT
Meningococcal ACWY Disease
PF-06741086
Hemophilia A
Clostridium difficile vaccine
Clostridium Difficile Associated Disease
DVS-SR
Major Depressive Disorder
Varenicline
Smoking
RSVpreF Vaccine
Respiratory Syncytial Virus
Enfortumab Vedotin
Urothelial Cancer
Levofloxacin
Community-Acquired Infections
daunorubicin + cytarabine
Leukemia, Myeloid, Acute
Dimebon
Alzheimer's Disease
PF-06801591
Advanced Malignancies
Desvenlafaxine Sustained Release
Fibromyalgia
Bacillus Calmette-Guerin
Non-muscle Invasive Bladder Cancer
IBU BID
Pain
PF-07248144
Breast Cancer
gemtuzumab ozogamicin
Leukemia
PF-06838435/fidanacogene elaparvovec
Hemophilia B
13vPnC + TIV
Pneumococcal Infections
CP-690,550 (tofacitinib)
Juvenile Idiopathic Arthritis
PF-02341066
Carcinoma, Non-Small-Cell Lung
Antibiotic
Pneumonia, Pneumococcal
Sunitinib + Capecitabine
Breast Neoplasms
Axitinib (AG-013736)
Hepatocellular Carcinoma
Osivelotor
Sickle Cell Disease
Azithromycin plus Chloroquine
Malaria
Tiotropium low dose QD
Asthma
DIC075V (intravenous diclofenac sodium)
Pain, Postoperative
PhXA41
Glaucoma
Interferon Alfa
Carcinoma, Renal Cell
13-valent Pneumoccocal Conjugate Vaccine
Pneumococcal Conjugate Vaccine
PF-08634404
Carcinoma, Hepatocellular
azithromycin (Zithromax)
Pneumonia
Group Hydroxychloroquine
Complication
Group Apixaban
Complication
Trastuzumab + Pertuzumab
HER2 Positive Breast Cancer
Temsirolimus (CCI-779)
Advanced Renal Cell Carcinoma
Tiotropium Respimat
Asthma
Glasdegib
Acute Myeloid Leukemia
chemotherapy
Leukemia
IV Iron
Chronic Kidney Disease (CKD)
fluoxetine
Major Depressive Disorder
olmesartan alone or in combination with hydrochlorothiazide
Essential Hypertension
MERREM I.V. as a 3 hour infusion every 8 hours
Pneumonia
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Hemophilia A
Ertapenem
Bacterial Infections
Inclacumab
Sickle Cell Disease
Amoxicillin/clavulinic acid
Bronchitis, Chronic
cefuroxime
Pneumonia
Ertugliflozin
Diabetes Mellitus, Type 2
Dazukibart
Dermatomyositis
azithromycin sustained release
Pneumonia
Azithromycin/Chloroquine
Malaria, Falciparum
Tiotropium high dose QD
Asthma
Mevrometostat
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Bapineuzumab 1.0 m/kg
Alzheimer's Disease
tiotropium Respimat high dose
Asthma
folic acid, vitamin B12 (cyanocobalamin)
Coronary Artery Disease
Group Hydroxychloroquine and apixaban
Complication
tiotropium Respimat low dose
Asthma
vitamin B6 (pyridoxine)
Coronary Artery Disease
Crisaborole Ointment
Atopic Dermatitis
Vanquix Auto-Injector (Diazepam Injection)
Seizures
Dexmedetomidine hydrochloride
Sedation
somatropin - GH treated cohort
Prader-Willi Syndrome
Rimegepant/BHV3000
Pediatric Migraine
PF-06438179
Rheumatoid Arthritis
Fentanyl
Anesthesia
Irinotecan + 5 FU + folinic acid
Colorectal Neoplasms
NSAID
Chronic Pain
Ritlecitinib lower dose
Severe Alopecia Areata
Epogen (Amgen)
Chronic Kidney Disease
PPSV23
Pneumococcal Disease
"Investigational"Auto-injector (sumatriptan succinate)
Migraine
VLA15
Lyme Borreliosis
Bococizumab (PF-04950615; RN316)
Hyperlipidemia
23-valent Pneumococcal Polysaccharide Vaccine
Pneumococcal Vaccines
BeneFIX
Hemophilia B
Background NSAID
Spondylitis, Ankylosing
VFEND® I.V., Oral
Candidiasis
DVS SR
Depressive Disorder, Major
PF-06821497
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Ribociclib
Breast Cancer
CP-945,598
Obesity
cabergoline
Restless Legs Syndrome
voriconazole (Vfend)
Candidiasis
Ceftriaxone sodium
Intra-abdominal Infections
Bazedoxifene Acetate (TSE-424)
Osteoporosis
Ibuprofen caplet
Patient Compliance
Bococizumab
Hyperlipidemia
Crisaborole
Atopic Dermatitis
somatropin - adult cohort
Prader-Willi Syndrome
Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
Depression
Topical IBU three times daily
Ankle Injuries
PF-08046054
Non-small Cell Carcinoma
CP-690, 550
Psoriasis
CAZ-AVI
Complicated Intra-Abdominal Infection
Berobenatide
Apnea
Cold-adapted influenza vaccine trivalent (CAIV-T)
Influenza
Milnacipran
Depression
naproxen
Osteoarthritis
Fentanyl/Morphine
Sedation
Ibuprofen
Post-surgical Pain Following Extraction of Molar Teeth
Temsirolimus
Renal Cell Carcinoma
Etoposide + cisplatin
Small Cell Lung Carcinoma
20-valent pneumococcal conjugate vaccine (20vPnC)
Pneumococcal Disease
Unfractionated Heparin (UFH)
Deep Vein Thrombosis
tolterodine tartrate
Overactive Bladder
Following the planned interim analysis for this study: Avelumab
Urothelial Cancer
bazedoxifene BZA-20
Postmenopause
rimegepant ODT
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Rapamune®
Kidney Disease
Pertuzumab
HER2 Positive Breast Cancer
Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Alopecia Areata
23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
HIV Infections
Anidulafungin
Neutropenia
adenosine
Coronary Artery Disease
Varenicline Tartarate
Smoking Cessation
Placebp
Respiratory Syncytial Virus
Treatment with Genotropin in different dosages
Growth Disorder
prinomastat
Brain and Central Nervous System Tumors
MEK162
Metastatic Colorectal Cancer
Abrocitinib
Atopic Dermatitis
5 fluorouracil
Metastatic Colorectal Cancer
LGX818
Solid Tumors Harboring a BRAF V600 Mutation
vemurafenib
Melanoma
Genotonorm (Somatropin)
Fetal Growth Retardation
Xyntha
Hemophilia A
Zavegepant (BHV-3500)
Acute Migraine
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Respiratory Syncytial Virus (RSV)
SU011248
Gastrointestinal Stromal Tumors
Seasonal Inactivated Influenza Vaccine
Respiratory Syncytial Virus
IV Diclofenac
Postoperative Pain
Piperacillin/Tazobactam (Tazocin)
Hematologic Neoplasms
effervescent ibuprofen tablets
Pain
CP690,550
Ulcerative Colitis
FOLFIRI regimen
Colorectal Cancer
clarithromycin extended release (ER)
Pneumonia
Xiapex
Dupuytren's Contracture
MTZ
Complicated Intra-abdominal Infection
vaccine-13vPnC
Pneumococcal Infections
PF-04965842
Atopic Dermatitis
ATM-AVI
Complicated Intra-Abdominal Infections, cIAIs
Recombinant Coagulation Factor IX (BeneFIX)
Hemophilia B
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
Encephalitis, Tick-Borne
Xalacom
Glaucoma, Open-Angle
Topical IBU twice daily
Ankle Injuries
PLD
Ovarian Cancer
Lorlatinib
Carcinoma, Non-Small-Cell Lung
Ibuprofen Immediate Release/Extended Release Caplet
Analgesia
Clostridium difficile
Clostridium Difficile Associated Disease
PD 0332334
Generalized Anxiety Disorder
Taxotere®
Early Breast Cancer
PD-0332991
Neoplasms
UFT
Colon Cancer
PF-07275315 dose 1
Moderate to Severe Chronic Obstructive Pulmonary Disease
PF-08653944
Obesity
Leuprolide Open Label
Hormone Sensitive Prostate Cancer
MabThera®
Follicular Lymphoma
MenACWY-CRM
Meningococcal Vaccine
DA-9501
Sedation
rLP2086
Healthy
Investigational Medical Product (IMP) administered in parent study
Osteoarthritis
VENLAFAXINE
Panic Disorders
PF-05280586
Rheumatoid Arthritis
PG4
Pneumococcal Disease
CE/MPA
Endometrial Hyperplasia
Quadrivalent influenza modRNA vaccine
Influenza, Human
voxelotor
Sickle Cell Disease
Standard Ibuprofen
Pain
23vPS
Vaccines, Pneumococcal Conjugate Vaccine
Zyvox®/Linezolid
Bacterial Infections
Megestrol acetate
Metastatic Breast Cancer
Fragmin/Dalteparin Sodium
Diabetic Foot Ulcer
Rimegepant Orally Disintegrating Tablets (ODT)
Acute Migraine
Lorazepam
Reflex Epilepsy, Photosensitive
RSVpreF MDV
Respiratory Syncytial Virus (RSV)
TBE vaccine
Tick-Borne Encephalitis
Exubera (inhaled insulin)
Diabetes Mellitus, Type 2
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Gaucher Disease
ibuzatrelvir
COVID-19 Infection
Inotuzumab ozogamicin
ACUTE LYMPHOBLASTIC LEUKEMIA
PF-00299804
Carcinoma, Non Small Cell Lung
7vPnC
Vaccines, Pneumococcal
FLAG (fludarabine, cytarabine and G-CSF)
Acute Lymphoblastic Leukemia
MenABCWY
Meningococcal Vaccine
PF-06462700
Aplastic Anemia
Multivalent Group B streptococcus vaccine
Group B Streptococcus Infections
Infanrix hexa
Healthy
PF-06651600 Induction Dose
Alopecia Areata
Either switch to oral therapy: of Ciprofloxacin (oral)
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
C.difficile vaccine
Clostridioides Difficile Associated Disease
Celebrex
Osteoarthritis,Knee
Abemaciclib
Breast Cancer
or switch to oral therapy:/of sulfamethoxazole/trimethoprim (oral)
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
propiverine
Urinary Bladder, Overactive
CAIV-T
Influenza
ATRA plus 6-MP and MTX
Leukemia, Myelocytic, Acute
Sirolimus (Rapamune®)
Renal Transplant
somatrogon
Growth Hormone Deficiency
ampicillin sodium/sulbactam sodium
Pneumonia, Bacterial
(PN-152,243)/PN-196,444
Neoplasms
Chemotherapy Regimen 1
Advanced Non-Small Cell Lung Cancer
ALO-02
Chronic Pain
exemestane (Aromasin)
Breast Neoplasms
somatropin - GH naïve pediatric cohort
Prader-Willi Syndrome
Sirolimus (RAPAMUNE)
Graft vs Host Disease
Irinotecan hydrochloride trihydrate
Esophageal Cancer
Meningococcal group C polysaccharide conjugate vaccine
Neisseria Meningitidis
pantoprazole for approximately 9 weeks
Gastroesophageal Reflux
Methotrexate - Immediate
Rheumatoid Arthritis
Moxifloxacin
Chronic Bronchitis
binodenoson
Coronary Artery Disease
Itraconazole
Antifungal Prophylaxis of Invasive Fungal Infections
bivalent rLP2086
Meningococcal Infection
Inhaled human insulin
Diabetes Mellitus, Type 1
relugolix, estradiol, norethindrone acetate
Endometriosis
Pneumo23/Pneumovax
Rheumatoid Arthritis
Hib
Pneumococcal Infections
FDC IBU/APAP
Pain
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Pneumococcal Disease
Elotuzumab
Multiple Myeloma
TS-1
Gastric Cancer
Axitinib plus Toripalimab
Renal Cell Carcinoma
Avelumab
Urothelial Cancer
FSME-IMMUN NEW
Tick-borne Encephalitis
Methotrexate - Delay
Rheumatoid Arthritis
rFIX-R
Hemophilia B
Sunitinib
Lymphoma, Non-Hodgkin
levoleucovorin
Colorectal Neoplasms
Bleomycin
Hodgkin Lymphoma
tiotropium Respimat® high dose
Asthma
HZ/su VACCINE
Respiratory Syncytial Virus (RSV)
leucovorin
Colorectal Carcinoma
Vinblastine
Hodgkin Lymphoma
PMI-150 (intranasal ketamine)
Pain, Postoperative
tiotropium Respimat® low dose
Asthma
CCI-779
Multiple Sclerosis, Relapsing-Remitting
Interferon Alfa and CCI-779
Carcinoma, Renal Cell
Aromatase Inhibitors
Metastatic Breast Cancer
Maraviroc (UK-427,857)
HIV Infections
amoxicillin/clavulanate postassium (Augmentin ES-600)
Acute Otitis Media
Advanced therapy only without dietary intervention
Ulcerative Colitis
Haematopoietic growth factor
Hodgkin Lymphoma
Chemotherapy Regimen 2
Carcinoma
Fulvestrant Injectable Product
Metastatic Breast Cancer
Optimized Background Therapy
HIV Infections
azithromycin SR
Acute Otitis Media
Dicloxacillin
Bacterial Infections
Oxacillin
Bacterial Infections
Ibuprofen/acetaminophen
Pain
Donepezil (Aricept)
Alzheimer Disease
Lorlatanib
Advanced Malignancies
Utomilumab
Stage III Breast Cancer
PF-06651600 Maintenance Dose #3
Alopecia Areata
Standard-of-Care plus Dexmedetomidine
Endotracheal Intubation
RSVpreF (Group 2)
RSV
diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
Healthy Subjects
PF-06651600 Maintenance Dose #1
Alopecia Areata
RSVpreF (Group 3)
RSV
SABER-Bupivacaine
Postoperative Pain
PF04965842
Atopic Dermatitis
recombinant human growth hormone
Abdominal Obesity
PF-06651600 Maintenance Dose #2
Alopecia Areata
CMP 001
Advanced Malignancies
PF04518600
Advanced Malignancies
BNT162b2
SARS-CoV-2 Infection
brentuximab vedotin
Lymphoma, B-Cell
Ketamine
Chronic Daily Headache
DVS-233 SR (desvenlafaxine sustained release)
Major Depressive Disorder
Insulin Lispro
Diabetes Mellitus
Cyclosporine A
Renal Transplantation
13 valent pneumococcal conjugate vaccine with Polysorbate 80
Vaccines, Pneumococcal
Meropenem
Complicated Intra-abdominal Infections
MET097
Obesity
RSVpreF (Group 1)
RSV
Imipenem-cilastatin
Skin Infection
Diclofenac
Spondylitis, Ankylosing
Pediacel
Vaccines, Pneumococcal
Pemetrexed/Cisplatin
NSCLC (Non-small Cell Lung Cancer)
Conventional amphotericin B
Candidiasis
bazedoxifene/conjugated estrogens
Menopause
azithromycin SR (Zithromax; compound: CP-62,993)
Maxillary Sinusitis
desvenlafaxine succinate (DVS) SR
Vasomotor Symptoms
PF-06823859
Myositis
axitinib
Carcinoma, Non-Small Cell Lung
Ritlecitinib
Stable Nonsegmental Vitiligo
Nonacog alfa
Hemophilia B
Novel Ibuprofen
Pain
AG-013736
Carcinoma, Pancreatic Ductal
Epoetin Hospira Arm
Chronic Kidney Disease (CKD)
Imipenem
Bacterial Pneumonia
marstacimab
Hemophilia A
Bosutinib
Polycystic Kidney, Autosomal Dominant
Inhaled Insulin
Asthma
Rimegepant
Acute Migraine
Bazedoxifene/Conjugate Estrogens (CE)
Endometrial Hyperplasia
7-valent Pneumococcal Conjugate Vaccine
Pneumococcal Infection
Modified Bolus 5-FU/LV with Irinotecan
Colorectal Neoplasms
varenicline (CP-526,555)
Smoking Cessation
Tigecycline
Gram-Positive Bacterial Infections
fesoterodine fumarate
Overactive Bladder
SPM 907
Overactive Bladder Syndrome
Somatropin
Endocrine System Diseases
Parecoxib Sodium/Valdecoxib
Pain
Palbociclib
Breast Cancer
DVS-233
Menopause
Tisotumab Vedotin
Cervical Cancer
13-valent pneumococcal conjugate vaccine
Pneumococcal Vaccines
AN2690 Topical
Onychomycosis of Toenails
AN2728 Topical
Dermatitis, Atopic
levonorgestrel/ethinyl estradiol
Menstruation Disturbances
Ritlecitinib higher dose
Severe Alopecia Areata
PF-07321332
COVID-19
Pentavac
Vaccines, Pneumococcal
Encorafenib
BRAF V600E-mutant Metastatic Colorectal Cancer
20-valent pneumococcal conjugate vaccine
Pneumococcal Disease
Talazoparib with enzalutamide
mCRPC
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)
Meningitis, Meningococcal
Genotropin
Idiopathic Short Stature
bapineuzumab
Alzheimer Disease
DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa
Allogeneic Haematopoietic Stem Cell Transplantation
Zavegepant
Migraine
[S,S]-Reboxetine
Fibromyalgia
PF-06651600
Active Non-segmental Vitiligo
Taliglucerase alfa
Gaucher Disease
PF-06410293
Rheumatoid Arthritis
linezolid
Febrile Neutropenia
Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
Neisseria Meningitidis (Bacterial Meningitis)
Desvenlafaxine succinate sustained-release (DVS SR)
Depression
Epirubicin with Cyclophosphamide, followed by a Taxane
Adenocarcinoma
Ceftazidime-avibactam
Complicated Intra-abdominal Infection
talazoparib plus enzalutamide
Prostate Cancer
Ibuprofen/Caffeine
Pain
PF-06947386
Complicated Intra-abdominal Infection
tucatinib
HER2-positive Breast Cancer
CP-690,550
Crohn's Disease
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
Encephalitis, Tick-borne
Bococizumab (PF-04950615;RN316)
Hyperlipidemia
ponsegromab
Non-small Cell Lung Cancer
Dexmedetomidine
Sedation
DVS-233 SR
Major Depressive Disorder
Dacomitinib (PF-00299804)
Non-Small Cell Lung Cancer
Genotropin (PN-180,307) Somatropin
Infant, Small for Gestational Age
sumanirole
Parkinson Disease
UK-390,957
Ejaculation
torcetrapib/atorvastatin
Hyperlipidemia
dalteparin
Venous Thromboembolism
RSVpreF
RSV Infection
disitamab vedotin
Urothelial Carcinoma
Fesoterodine
Overactive Bladder Syndrome
Nimenrix
Meningococcal Vaccine
7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
Healthy Subjects
Meningococcal vaccine GSK134612
Infections, Meningococcal
13-valent pneumococcal conjugate vaccine (13vPnC)
Healthy Subjects
Moroctocog alfa (AF-CC)
Hemophilia A
lecozotan SR (SRA-333)
Alzheimer Disease
7 valent pneumococcal conjugate vaccine
Vaccines, Pneumococcal
Inhaled human insulin (EXUBERA™)
Diabetes Mellitus, Type 2
Tolterodine ER
Overactive Bladder
Fragmin
Diabetic Foot Ulcer
Tafamidis
Transthyretin (TTR) Amyloid Cardiomyopathy
Interferon-alfa
Carcinoma, Renal Cell
tanezumab
Arthritis
13vPnC
Vaccines, Pneumococcal Conjugate Vaccine
Rifabutin
Mycoses
endocrine-modulating drug therapy
Prostate Cancer
Ibuprofen Sodium
Pain
ceftazidim-avibactam (CAZ-AVI, experimental product)
Nosocomial Pneumonia (NP)
leflunomide
Prostate Cancer
Cyclosporin or tacrolimus
Graft Rejection
Edotecarin
Breast Neoplasms
Ceftaroline fosamil
Complicated Skin and Soft Tissue Infection
Sasanlimab
Urothelial Carcinoma Bladder
DTP/Hib
Meningitis, Meningococcal
NMDA Antagonist, CP-101,606 (traxoprodil)
Depressive Disorder, Major
MultiStem high dose
Colitis, Ulcerative
maraviroc (Selzentry)
HIV Infections
Vaccine Candidate #1
Healthy Adults
AN2898
Dermatitis, Atopic
PF-08653945
Overweight
Dorzolamide
Glaucoma
PF-08049820
Atopic Dermatitis
PF-06826647
Psoriasis
Allegra
Allergic Rhinitis
Letrozole/Temsirolimus (CCI-779)
Breast Neoplasms
AG-013726
Colorectal Neoplasms
EXC 001 (currently called PF-06473871)
Reduction in Severity of Skin Scarring
Carfilzomib, proteasome inhibitor; intravenous
Advanced Multiple Myeloma
PF-06835919
Non-alcoholic Steatohepatitis
PF-07850327, ARV-471, vepdegestrant
Locally Advanced or Metastatic ER+ HER2- Breast Cancer
CP-690-550
Arthritis, Rheumatoid
SU-011,248
Kidney Neoplasms
Sunitinib (SU011248)
Liver Neoplasms
Tygacil
Bacterial Infections
tacedinaline
Pancreatic Cancer
Multivalent Pneumococcal Vaccine - Formulation 1
Pneumococcal Disease
SU011248, Sutent
Papillary Thyroid Cancer
Multivalent Pneumococcal Vaccine - Formulation 2
Pneumococcal Disease
PF-04217329 - Lowest Dose
Primary Open-Angle Glaucoma
(Part C) MET097
Obesity and Overweight
inotuzumab ozogamicin (CMC-544)
Lymphoma, B-Cell
PF-07104091 monotherapy dose escalation
Small Cell Lung Cancer
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Parkinson's Disease
Capecitabine tablets
Leptomeningeal Metastasis
PF-06291874
Diabetes Mellitus, Type II
Bupivacaine TTS (Bupivacaine Patch)
Chronic Low Back Pain
MRE0094
Foot Ulcer, Diabetic
(CP-690,550) Tofacitinib
Plaque Psoriasis
PF-03654746
Excessive Daytime Sleepiness
PF-06882961
Diabetes
PF-00489791
Diabetic Nephropathies
PF-00217830
Schizophrenia
UK-453, 061
HIV-1
EKB-569
Colorectal Neoplasms
Multivalent Pneumococcal Vaccine - Formulation 3
Pneumococcal Disease
ARRY-502, CRTh2 antagonist; oral
Asthma
Levonorgestrel
Ovulation
Formulation A
Respiratory Tract Infections
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
Shingles
CPG 7909 Injection
Carcinoma, Melanoma
Low dose cytarabine
Acute Myeloid Leukemia
Multivalent Pneumococcal Vaccine - Formulation 4
Pneumococcal Disease
Phase Ib ARRY-614 + nivolumab+ipilimumab
Renal Cell Carcinoma
Multivalent
Pneumococcal Infections
Filibuvir
Hepatitis
CP-690,550 + methotrexate
Rheumatoid Arthritis
Samuraciclib
Breast Cancer
AN2728
Psoriasis
PF-06823859 low
Dermatomyositis
PF-04494700 (TTP488)
Diabetic Nephropathy
QS-21
Alzheimer Disease
Selenomethionine (SLM)
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
PF-04937319
Type 2 Diabetes Mellitus
BGJ398
Melanoma
ARRY-438162, MEK inhibitor; oral
Rheumatoid Arthritis
ACC-001
Alzheimer's Disease
FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
Unresectable or Metastatic Colorectal Cancer
PF-05089771
Postoperative Dental Pain
SKI-606 (Bosutinib)
Chronic Myelogenous Leukemia
PF-00610355
Pulmonary Disease, Chronic Obstructive
PF-04217329 - High Dose
Primary Open-Angle Glaucoma
PBO
Hypercholesterolemia
PF-299804 (Dacomitinib)
Glioblastoma
PF-04136309
Osteoarthritis, Knee
vepdegestrant
Breast Cancer
PF-04236921
Crohn's Disease
Pentostatin
Chronic Lymphocytic Leukemia
Meningococcal C
Meningitis, Meningococcal
PD 0348292
Venous Thrombosis
PF-06835919 Low Dose
Non-alcoholic Fatty Liver Disease
Axitinib Oral Tablet
Renal Cell Carcinoma
PF-04457845
Osteoarthritis, Knee
BAT
Gram-negative Bacterial Infections
Anrukinzumab
Colitis, Ulcerative
PH-797804
Pulmonary Disease, Chronic Obstructive
UK-369,003
Prostatic Hyperplasia
Tucatinib in Combination of Oral VP16 and trastuzumab
HER2-positive Breast Cancer
Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
Renal Cell Carcinoma
Taxotere (docetaxel)
Prostatic Neoplasms
PF-07868489
Pulmonary Arterial Hypertension
Nicotine Adaptive Protocol
Nicotine Dependence
High Dose PF-07328948
Heart Failure
exemestane (Aromasin®)
Breast Neoplasms
SS-RBX
Urinary Incontinence, Stress
PF-06650833
Acne Inversa
Bosutinib (Phase 2 part)
Amyotrophic Lateral Sclerosis
PF - 00610355
Pulmonary Disease, Chronic Obstructive
Tucatinib (ONT-380)
Metastatic Breast Cancer ( HER2 Negative)
Elranatamab (PF-06863135)
Multiple Myeloma
PF-00734200
Diabetes Mellitus, Type 2
Anti-Beta Interferon (PF-06823859)
Dermatomyositis
mPnC candidate
Healthy Participants
PF-07220060 + PF-07104091 combination dose escalation
Breast Cancer
EXC 001
Scar Prevention
SAM-531
Alzheimer Disease
Trastuzumab plus Pertuzumab
Lymphoma, Non-Hodgkin
mIRV
Influenza, Human
PF- 00610355
Pulmonary Disease, Chronic Obstructive
Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor inhibitor
Kidney Neoplasms
CP-778,875
Dyslipidemia
Atomoxetine
Attention Deficit Disorder With Hyperactivity
CP-533, 536
Tibial Fractures
SBI-087
Active Rheumatoid Arthritis
Methotrexate plus ERB-041
Rheumatoid Arthritis
PF-04494700 - Low Dose Arm
Alzheimer Disease
RN624 (PF-04383119)
Osteoarthritis
Elranatamab + Nirogacestat
Multiple Myeloma
rhBMP-2/CPM
Fractures
ACC-001 + QS21
Alzheimer Disease
CE-224,535
Arthritis, Rheumatoid
BNT162b2 (Omi XBB.1.5)/RIV
Influenza, Human
Hormone therapy
Metastatic Breast Cancer With a Isolated Brain Progression
MultiStem low dose
Colitis, Ulcerative
Doxil
Breast Cancer
Doxorubicin Hydrochloride
Hodgkin Lymphoma
Sitexsentin sodium
Diastolic Heart Failure
SPK-9001
Hemophilia B
CP-866,087
Alcoholism
Tucatinib Oral Tablet
Leptomeningeal Metastasis
AG013736
Thyroid Neoplasms
PF-07275315
Asthma
ARRY-371797, p38 inhibitor; oral
LMNA-Related Dilated Cardiomyopathy
Phase II ARRY-614 + nivolumab
Renal Cell Carcinoma
CP-751,871
Prostatic Neoplasms
CPG10101
Hepatitis, Chronic Active
PF-06372865
Chronic Low Back Pain
CMC-544 (Inotuzumab Ozogamycin)
Acute Lymphoblastic Leukemia
RSV Vaccine
Respiratory Tract Infection
Elrantamab
Multiple Myeloma
PF-04383119 (tanezumab)
Osteoarthritis, Knee
Investigational drug
Carcinoma, Non-Small-Cell Lung
SU011248 capsule
Carcinoma, Renal Cell
interferon beta treatment to add-on atorvastatin treatment
Relapsing Remitting Multiple Sclerosis
Dacomitinib
Non-small Cell Lung Cancer
PF-00232798
HIV
SB-525 (PF-07055480)
Hemophilia A
PF-07817883
SARS-CoV-2 Infection
Belinostat
Metastatic Uveal Melanoma
Medium Dose PF-07328948
Heart Failure
PF06700841
Active Non-segmental Vitiligo
ILV-094
Rheumatoid Arthritis
pneumococcal polysaccharide and protein conjugate vaccines
Pneumococcal Infections
Crizotinib (PF-02341066)
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma
Paclitaxel,Gemcitabine,Sunitinib
Breast Cancer
Low Dose PF-07328948
Heart Failure
SU011248 (sunitinib)
Carcinoma, Renal Cell Metastasis
Linezolid (TIW)
Tuberculosis, Multidrug-Resistant
Rapamune® (Sirolimus)
Kidney Transplantation
SD-6010
Osteoarthritis
CP-690,550 Ointment 1
Psoriasis
AN2690
Onychomycosis
Gardasil
Vaccines
Sertraline and Elzasonan Combination
Depressive Disorder, Major
Ponezumab
Cerebral Amyloid Angiopathy
PF-00868554
Hepatitis C
maplirpacept (PF-07901801)
Diffuse Large B-Cell Lymphoma
Vaccine
Meningococcal Vaccine
bIRV AA
Influenza, Human
Licensed pediatric hepatits A vaccine
MENINGOCOCCAL INFECTION
SU014813
Breast Neoplasms
Tdap
Pneumococcal Infections
rLP2086 + MCV4 + Tdap
Vaccines
Temsirolimus and Sorafenib
Thyroid Cancer
Ceftazidime -avibactam
Complicated Urinary Tract Infections
Atovaquone
Bacterial Infections
(CP-6890,550) Tofacitinib
Plaque Psoriasis
CP-547,632
Ovarian Neoplasms
Esreboxetine
Fibromyalgia
UK-453,061
HIV-1
PF-06473871
Reduction of Hypertrophic Skin Scarring
15-valent pneumococcal conjugate vaccine (PCV15)
Pneumococcal Disease
untreated to atorvastatin treatment
Relapsing Remitting Multiple Sclerosis
Sulfamethoxazole-Trimethoprim
Bacterial Infections
RIV
Influenza, Human
rLP2086 and Gardasil
Vaccines
Sunitinib Malate Continuous Daily Dosing
Carcinoma, Renal Cell
PF-00446687
Erectile Dysfunction
NXL104/ceftazidime
Complicated Urinary Tract Infection
Duavee
Breast Cancer
ERB-041
Endometriosis
bIRV AB
Influenza, Human
AG-013736 (Axitinib)
Acute Myeloid Leukemia (AML)
temsirolimus plus liposomal doxorubicin
Sarcoma
LEE011
Locally Advanced or Metastatic NRAS Mutant Melanoma
Macugen ™ (pegaptanib sodium injection)
Macular Degeneration
7-valent pneumococcal conjugate vaccine (vaccine)
HIV Infections
PF-07976016
Obesity
qIRV
Influenza, Human
PF-04494700
Alzheimer's Disease
CP-751, 871
Colorectal Neoplasm
PF-610,355
Asthma
CP-690,550 Eye drops
Dry Eye Syndromes
CP-690,550 Ointment 2
Psoriasis
Tofimilast
Asthma
Tiotropium bromide
Asthma
Tick-borne Encephalitis Vaccine
Tick-borne Encephalitis
PF-02545920
Huntington's Disease
Sumatriptan
Migraine
bIRV BB
Influenza, Human
PF-04991532
Diabetes Mellitus, Type 2
ceftazidime/NXL104 + metronidazole
Complicated Intra-abdominal Infections
INC280
Melanoma
MAC-321
Colorectal Neoplasms
Combination [RSVpreF+BNTb162b2]
Healthy Participants
PD-0299685
Hot Flashes
tiotropium-bromide
Asthma
Dexmedetomidine, midazolam; fentanyl
Intubated and Mechanically Ventilated Pediatric Subjects
CP- 690 550
Ulcerative Colitis
PF-04191834
Asthma
PF-04171327
Rheumatoid Arthritis
Gemtuzumab Ozogamicin (GO)
Acute Myeloid Leukemia
23-valent pneumococcal conjugate vaccine (vaccine)
HIV Infections
Anti-NGF AB
Neoplasms
Mylotarg (gemtuzumab ozogamicin) Injection
Acute Myelogenous Leukemia
ACC-001 (vanutide cridificar)
Alzheimer's Disease
PD 0299685
Interstitial Cystitis
Elranatamab injection
Refractory Multiple Myeloma
PF-06882961 (Cohorts 1 and 2)
Obesity
Bazedoxifene
Postmenopausal Osteoporosis
PF-05221304
Nonalcoholic Fatty Liver Disease
ARRY-520, KSP(Eg5) inhibitor; intravenous
Multiple Myeloma
ALO-01
Healthy
FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
Colorectal Neoplasms
Capravirine
Human Immunodeficiency Virus
Bivalent rLP2086 Vaccine
MENINGOCOCCAL INFECTION
Prevenar13
IgG Deficiency
TMI-005
Rheumatoid Arthritis
Combination 1
Carcinoma, Renal Cell
BNT162b2 (Omi XBB.1.5)
Influenza, Human
Influenza ModRNA Vaccine
Influenza, Human
ATM-AVI Single Dose, Cohorts 1-4
Gram-negative Bacterial Infection
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)
Group B Streptococcal Infections
Investigational Influenza Vaccine
Influenza
meningococcal B rLP2086 vaccine
Meningitis, Meningococcal
Anti-OX40 Antibody PF-04518600
Stage III Breast Cancer
FUFA
Colorectal Cancer
PF-04217329 - Low Dose
Primary Open-Angle Glaucoma
PF-04217329 - High Middle Dose
Primary Open-Angle Glaucoma
PF-07264660
Atopic Dermatitis
PF-3512676
Lymphoma, T-Cell, Cutaneous
PF-00592379
Impotence
sulopenem and PF-03709270
Pneumonia, Bacterial
PF-4217329 - Highest Dose
Primary Open-Angle Glaucoma
PF-07038124 ointment
Atopic Dermatitis
Rapamycin
Nonmalignant Neoplasm
WNT974
Metastatic Colorectal Cancer
sunitinib malate dose escalation
Gastrointestinal Stromal Tumors
Tetanus, diphtheria, and acellular pertussis vaccine
Group B Streptococcus Infections
PF-04447943
Alzheimer's Disease
PD 0332991
Breast Cancer
PF-06835375
Primary Immune Thrombocytopenia
Torisel
Adenocarcinoma
meningococcal B rLP2086 vaccine candidate
Meningitis, Meningococcal
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
Lung Cancer (NSCLC)
ARRY-334543, EGFR/ErbB2 inhibitor; oral
Advanced Cancer
Recombinant Human Interleukin-11 (rhIL-11)
Crohn Disease
sitaxsentan (Thelin)
Cardiac Surgery Subjects
Bosutinib (Phase 1 part)
Amyotrophic Lateral Sclerosis
C. difficile vaccine (previously studied formulation)
Clostridoides Difficile Associated Disease
PF-07038124
Atopic Dermatitis
Kaletra
HIV Infections
PF-05221304 Monotherapy
Non-Alcoholic Fatty Liver Disease (NAFLD)
Alclometasone cream
Non Small Cell Lung Cancer (NSCLC)
852A
Melanoma
PD 0200390
Nonrestorative Sleep
PF-03654764
Allergic Rhinitis
PD0332991
Breast Neoplasms
MET233 and MET097
Obesity and Obesity-related Medical Conditions
Vemurafenib plus Cobimetinib
Lymphoma, Non-Hodgkin
vabicaserin
Schizophrenia
CI-1033
Breast Neoplasms
CE-326,597
Weight Management
PF00299804
Advanced Gastric Cancer
Repevax
Meningococcal Vaccine
CI 1033
Lung Neoplasms
PF-04383119
Cystitis, Interstitial
Open
Chronic Kidney Disease
Guaifenesin
Chronic Rhinitis
PF-06838435 (formerly SPK-9001)
Hemophilia B
RN624
Neuralgia, Postherpetic
PD-217,014
Irritable Bowel Syndrome
HSP-130
Non-metastatic Breast Cancer
Axitinib [AG-013736]
Melanoma
IMA-638
Asthma
PF-03446962
Malignant Pleural Mesothelioma
CP-526,555 (varenicline)
Smoking Cessation
Tolterodine & Pregabalin
Overactive Bladder
MET233
Obesity and Overweight
SCA-136
Schizophrenia
ACC-001/QS-21
Alzheimer's Disease
Tisotumab vedotin (HuMax-TF-ADC)
Ovary Cancer
Tamsulosin
Prostatic Hyperplasia
PF-06835919 High Dose
Non-alcoholic Fatty Liver Disease
Creatine
Amyotrophic Lateral Sclerosis
IMA-638 is a biologic
Asthma
CPG 7909
Carcinoma, Non-Small Cell Lung
Vupanorsen
Dyslipidemias
Staphylococcus aureus 4-antigen vaccine
Staphylococcal Infections
SGN-35
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma
Herceptin®
Carcinoma, Metastatic Breast
PF-07220060 CDK4 inhibitor
Advanced or Metastatic Breast Cancer
Peg-Intron
Hepatitis C
PF-06700841
Psoriatic Arthritis
Filanesib, KSP (Eg5) inhibitor; intravenous
Advanced Multiple Myeloma
Pediatric HAV vaccine
Meningococcal B Disease
Gemcitabine, nucleoside analogue; intravenous
Advanced Cancer
RV521
Respiratory Syncytial Virus Infections
Naproxen + PH-797804
Osteoarthritis
Irinotecan plus capecitabine
Carcinoma, Hepatocellular
Tasocitinib plus Methotrexate
Rheumatoid Arthritis
FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Colorectal Neoplasms
PF-04236921 SC injection
Crohn's Disease
PF-04634817
Diabetic Nephropathy
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Depression
ACC-001 + QS-21
Alzheimer Disease
cytarabine
Acute Myeloid Leukemia
ARRY-371797, p38 inhibitor, oral
LMNA-Related Dilated Cardiomyopathy
PELITREXOL/AG-2037
Colorectal Neoplasms
Phase Ib ARRY-614 + nivolumab
Renal Cell Carcinoma
Combination Agent 1
Advanced/Metastatic Non-Small Cell Lung Cancer
Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Renal Cell Carcinoma
UK0369,003
Impotence
PF-04449913
Acute Myeloid Leukemia
PF-04217329
Glaucoma, Open-Angle
Statin
Hypercholesterolemia
lecozotan SR
Alzheimer Disease
Tucatinib in Combination with Palbociclib and Letrozole
Breast Cancer
BYL719
Colorectal Cancer
MYO-029
Becker Muscular Dystrophy
Temodar and Irinotecan
Glioblastoma
MET097 Injection
Obesity in Diabetes
SRA-333
Alzheimer's Disease
CI-1040
Colorectal Neoplasms
Varenicline Adaptive Protocol
Nicotine Dependence
PF-04950615 (RN316)
Hypercholesterolemia
PF-04360365
Alzheimer's Disease
PF-06463922
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Sunitinib malate (SU011248)
Gastrointestinal Stromal Tumors
Gefitinib + Sunitinib
Carcinoma, Renal Cell
Pertuzumab/Trastuzumab
Metastatic Breast Cancer With a Isolated Brain Progression
PF-04383119 (RN624)
Low Back Pain
PF-06865571
Nonalcoholic Steatohepatitis
PF-04217329 - Middle Dose
Primary Open-Angle Glaucoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epoetin Hospira | Phase 3 | Chronic Renal Failure Requiring Hemodialysis | - | - |
Remicade | Phase 3 | Crohn's Disease | - | - |
Enbrel (etanercept) | Phase 3 | Ankylosing Spondylitis | - | - |
Zmax | Phase 3 | Otitis Media | - | - |
Venlafaxine ER | Phase 3 | Panic Disorder | - | - |
Levonorgestrel and Ethinyl Estradiol | Phase 3 | Oral Contraceptive | - | - |
ARV-471 | Phase 3 | Advanced Breast Cancer | - | - |
ARV-471 (PF-07850327) | Phase 3 | Breast Cancer | - | - |
heptavalent pneumococcal conjugate vaccine, Prevenar | Phase 3 | Allogeneic Haematopoietic Stem Cell Transplantation | - | - |
valdecoxib | Phase 3 | Pain | - | - |
Havrix (HAV) | Phase 3 | Meningococcal Vaccine | - | - |
NWP09 | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
PF-07220060 | Phase 3 | Liposarcoma | - | - |
Diflucan IV, oral | Phase 3 | Candidiasis | - | - |
Rimegepant (PF-07899801) | Phase 3 | Acute Treatment of Migraine | - | - |
13 valent Pneumococcal Conjugate Vaccine | Phase 3 | Pneumococcal Infections | - | - |
7vPnc pneumococcal conjugate vaccine | Phase 3 | Vaccines, Pneumococcal | - | - |
Bifeprunox | Phase 3 | Schizophrenia | - | - |
CT-P13 | Phase 3 | Crohn's Disease | - | - |
Sunitinib malate | Phase 3 | Breast Neoplasms | - | - |
Ethambutol hydrochloride | Phase 3 | Mycobacterium Avium-intracellulare Infection | - | - |
ritonavir | Phase 3 | COVID-19 | - | - |
ReFacto AF | Phase 3 | Hemophilia A | - | - |
binimetinib | Phase 3 | MSS | - | - |
ropinirole | Phase 3 | Parkinson Disease | - | - |
Desvenlafaxine Succinate Sustained-Release | Phase 3 | Major Depressive Disorder | - | - |
Ceftazidime - Avibactam (CAZ-AVI) | Phase 3 | Complicated Urinary Tract Infection | - | - |
Etanercept | Phase 3 | Pulmonary Fibrosis | - | - |
Avelumab (MSB0010718C) | Phase 3 | Renal Cell Cancer | - | - |
Steroids | Phase 3 | Kidney Failure | - | - |
rFIX | Phase 3 | Hemophilia B | - | - |
In open-label phase: treatment with tofacitinib | Phase 3 | Arthritis Juvenile Idiopathic | - | - |
Ibuprofen ER | Phase 3 | Pain | - | - |
cefuroxime plus erythromycin | Phase 3 | Pneumonia | - | - |
PF-05280014 | Phase 3 | Metastatic Breast Cancer | - | - |
Quillivant Oral Suspension XR | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
Prevenar 13™ | Phase 3 | Infections, Meningococcal | - | - |
Desvenlafaxine Succinate | Phase 3 | Major Depressive Disorder | - | - |
Enzalutamide | Phase 3 | Breast Cancer | - | - |
Voriconazole | Phase 3 | Neutropenia | - | - |
indobufen | Phase 3 | Atrial Fibrillation | - | - |
desvenlafaxine | Phase 3 | Depressive Disorder, Major | - | - |
Isovorin | Phase 3 | Gastric Cancer | - | - |
Nirmatrelvir | Phase 3 | COVID-19 | - | - |
Doripenem | Phase 3 | Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis | - | - |
Midazolam | Phase 3 | Sedation | - | - |
Artemether-lumefantrine | Phase 3 | Malaria, Falciparum | - | - |
Crizotinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
Rapamune | Phase 3 | Renal Allograft Recipients | - | - |
Effexor XR | Phase 3 | Depression | - | - |
Fesoterodine PR | Phase 3 | Urinary Bladder, Neurogenic | - | - |
desipramine | Phase 3 | Depression | - | - |
procarbazine hydrochloride | Phase 3 | Brain and Central Nervous System Tumors | - | - |
desvenlafaxine succinate sustained release | Phase 3 | Vasomotor Symptoms | - | - |
Anidulafungin, VER002 | Phase 3 | Aspergillosis | - | - |
treatment | Phase 3 | Non Squamous Lung Cancer | - | - |
Tofacitinib | Phase 3 | Rheumatoid Arthritis | - | - |
Etrasimod | Phase 3 | Alopecia Areata | - | - |
Elranatamab | Phase 3 | Multiple Myeloma | - | - |
Fenofibrate | Phase 3 | Hyperlipidemia | - | - |
Disease-modifying antirheumatic drug | Phase 3 | Arthritis, Rheumatoid | - | - |
20vPnC | Phase 3 | Pneumococcal Disease | - | - |
Genotonorm | Phase 3 | Growth Disorders | - | - |
Varenicline tartrate | Phase 3 | Smoking Cessation | - | - |
pegaptanib sodium | Phase 3 | Macular Degeneration | - | - |
rLP2086 vaccine | Phase 3 | Meningitis, Meningococcal | - | - |
Apixaban | Phase 3 | Atrial Fibrillation | - | - |
Talazoparib | Phase 3 | Prostate Cancer | - | - |
Fx-1006A | Phase 3 | Familial Amyloid Polyneuropathy | - | - |
Sulfadoxine-Pyrimethamine/Chloroquine | Phase 3 | PLASMODIUM FALCIPARUM MALARIA | - | - |
Mefloquine | Phase 3 | Malaria, Falciparum | - | - |
CP 690,550 | Phase 3 | Rheumatoid Arthritis | - | - |
PN-152,243)/PN-196,444 | Phase 3 | Sarcoma | - | - |
Physician's-Choice | Phase 3 | Breast Neoplasms | - | - |
Bazedoxifene Acetate | Phase 3 | Osteoporosis | - | - |
gemcitabine hydrochloride | Phase 3 | Lung Cancer | - | - |
Sigvotatug Vedotin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Epogen Amgen | Phase 3 | Chronic Renal Failure | - | - |
desvenlafaxine SR | Phase 3 | Depression | - | - |
PVC (daily, 7 days off) | Phase 3 | Atrophic Vaginitis | - | - |
Dexmedetomidine HCL Injection | Phase 3 | Awake Fiberoptic Intubation | - | - |
Bazedoxifene/Conjugated Estrogen | Phase 3 | Vaginal Atrophy | - | - |
desvenlafaxine succinate sustained release tablets | Phase 3 | Major Depressive Disorder | - | - |
Cyclosporine | Phase 3 | Kidney Transplant | - | - |
Amphotericin B | Phase 3 | Mycoses | - | - |
Pegvisomant | Phase 3 | Acromegaly | - | - |
Ceftaroline | Phase 3 | Community-Acquired Bacterial Pneumonia | - | - |
MenACWY-TT | Phase 3 | Meningococcal ACWY Disease | - | - |
PF-06741086 | Phase 3 | Hemophilia A | - | - |
Clostridium difficile vaccine | Phase 3 | Clostridium Difficile Associated Disease | - | - |
DVS-SR | Phase 3 | Major Depressive Disorder | - | - |
Varenicline | Phase 3 | Smoking | - | - |
RSVpreF Vaccine | Phase 3 | Respiratory Syncytial Virus | - | - |
Enfortumab Vedotin | Phase 3 | Urothelial Cancer | - | - |
Levofloxacin | Phase 3 | Community-Acquired Infections | - | - |
daunorubicin + cytarabine | Phase 3 | Leukemia, Myeloid, Acute | - | - |
Dimebon | Phase 3 | Alzheimer's Disease | - | - |
PF-06801591 | Phase 3 | Advanced Malignancies | - | - |
Desvenlafaxine Sustained Release | Phase 3 | Fibromyalgia | - | - |
Bacillus Calmette-Guerin | Phase 3 | Non-muscle Invasive Bladder Cancer | - | - |
IBU BID | Phase 3 | Pain | - | - |
PF-07248144 | Phase 3 | Breast Cancer | - | - |
gemtuzumab ozogamicin | Phase 3 | Leukemia | - | - |
PF-06838435/fidanacogene elaparvovec | Phase 3 | Hemophilia B | - | - |
13vPnC + TIV | Phase 3 | Pneumococcal Infections | - | - |
CP-690,550 (tofacitinib) | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
PF-02341066 | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Antibiotic | Phase 3 | Pneumonia, Pneumococcal | - | - |
Sunitinib + Capecitabine | Phase 3 | Breast Neoplasms | - | - |
Axitinib (AG-013736) | Phase 3 | Hepatocellular Carcinoma | - | - |
Osivelotor | Phase 3 | Sickle Cell Disease | - | - |
Azithromycin plus Chloroquine | Phase 3 | Malaria | - | - |
Tiotropium low dose QD | Phase 3 | Asthma | - | - |
DIC075V (intravenous diclofenac sodium) | Phase 3 | Pain, Postoperative | - | - |
PhXA41 | Phase 3 | Glaucoma | - | - |
Interferon Alfa | Phase 3 | Carcinoma, Renal Cell | - | - |
13-valent Pneumoccocal Conjugate Vaccine | Phase 3 | Pneumococcal Conjugate Vaccine | - | - |
PF-08634404 | Phase 3 | Carcinoma, Hepatocellular | - | - |
azithromycin (Zithromax) | Phase 3 | Pneumonia | - | - |
Group Hydroxychloroquine | Phase 3 | Complication | - | - |
Group Apixaban | Phase 3 | Complication | - | - |
Trastuzumab + Pertuzumab | Phase 3 | HER2 Positive Breast Cancer | - | - |
Temsirolimus (CCI-779) | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Tiotropium Respimat | Phase 3 | Asthma | - | - |
Glasdegib | Phase 3 | Acute Myeloid Leukemia | - | - |
chemotherapy | Phase 3 | Leukemia | - | - |
IV Iron | Phase 3 | Chronic Kidney Disease (CKD) | - | - |
fluoxetine | Phase 3 | Major Depressive Disorder | - | - |
olmesartan alone or in combination with hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
MERREM I.V. as a 3 hour infusion every 8 hours | Phase 3 | Pneumonia | - | - |
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy | Phase 3 | Hemophilia A | - | - |
Ertapenem | Phase 3 | Bacterial Infections | - | - |
Inclacumab | Phase 3 | Sickle Cell Disease | - | - |
Amoxicillin/clavulinic acid | Phase 3 | Bronchitis, Chronic | - | - |
cefuroxime | Phase 3 | Pneumonia | - | - |
Ertugliflozin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Dazukibart | Phase 3 | Dermatomyositis | - | - |
azithromycin sustained release | Phase 3 | Pneumonia | - | - |
Azithromycin/Chloroquine | Phase 3 | Malaria, Falciparum | - | - |
Tiotropium high dose QD | Phase 3 | Asthma | - | - |
Mevrometostat | Phase 3 | Metastatic Castration Sensitive Prostate Cancer (mCSPC) | - | - |
Bapineuzumab 1.0 m/kg | Phase 3 | Alzheimer's Disease | - | - |
tiotropium Respimat high dose | Phase 3 | Asthma | - | - |
folic acid, vitamin B12 (cyanocobalamin) | Phase 3 | Coronary Artery Disease | - | - |
Group Hydroxychloroquine and apixaban | Phase 3 | Complication | - | - |
tiotropium Respimat low dose | Phase 3 | Asthma | - | - |
vitamin B6 (pyridoxine) | Phase 3 | Coronary Artery Disease | - | - |
Crisaborole Ointment | Phase 3 | Atopic Dermatitis | - | - |
Vanquix Auto-Injector (Diazepam Injection) | Phase 3 | Seizures | - | - |
Dexmedetomidine hydrochloride | Phase 3 | Sedation | - | - |
somatropin - GH treated cohort | Phase 3 | Prader-Willi Syndrome | - | - |
Rimegepant/BHV3000 | Phase 3 | Pediatric Migraine | - | - |
PF-06438179 | Phase 3 | Rheumatoid Arthritis | - | - |
Fentanyl | Phase 3 | Anesthesia | - | - |
Irinotecan + 5 FU + folinic acid | Phase 3 | Colorectal Neoplasms | - | - |
NSAID | Phase 3 | Chronic Pain | - | - |
Ritlecitinib lower dose | Phase 3 | Severe Alopecia Areata | - | - |
Epogen (Amgen) | Phase 3 | Chronic Kidney Disease | - | - |
PPSV23 | Phase 3 | Pneumococcal Disease | - | - |
"Investigational"Auto-injector (sumatriptan succinate) | Phase 3 | Migraine | - | - |
VLA15 | Phase 3 | Lyme Borreliosis | - | - |
Bococizumab (PF-04950615; RN316) | Phase 3 | Hyperlipidemia | - | - |
23-valent Pneumococcal Polysaccharide Vaccine | Phase 3 | Pneumococcal Vaccines | - | - |
BeneFIX | Phase 3 | Hemophilia B | - | - |
Background NSAID | Phase 3 | Spondylitis, Ankylosing | - | - |
VFEND® I.V., Oral | Phase 3 | Candidiasis | - | - |
DVS SR | Phase 3 | Depressive Disorder, Major | - | - |
PF-06821497 | Phase 3 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
CP-945,598 | Phase 3 | Obesity | - | - |
cabergoline | Phase 3 | Restless Legs Syndrome | - | - |
voriconazole (Vfend) | Phase 3 | Candidiasis | - | - |
Ceftriaxone sodium | Phase 3 | Intra-abdominal Infections | - | - |
Bazedoxifene Acetate (TSE-424) | Phase 3 | Osteoporosis | - | - |
Ibuprofen caplet | Phase 3 | Patient Compliance | - | - |
Bococizumab | Phase 3 | Hyperlipidemia | - | - |
Crisaborole | Phase 3 | Atopic Dermatitis | - | - |
somatropin - adult cohort | Phase 3 | Prader-Willi Syndrome | - | - |
Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR) | Phase 3 | Depression | - | - |
Topical IBU three times daily | Phase 3 | Ankle Injuries | - | - |
PF-08046054 | Phase 3 | Non-small Cell Carcinoma | - | - |
CP-690, 550 | Phase 3 | Psoriasis | - | - |
CAZ-AVI | Phase 3 | Complicated Intra-Abdominal Infection | - | - |
Berobenatide | Phase 3 | Apnea | - | - |
Cold-adapted influenza vaccine trivalent (CAIV-T) | Phase 3 | Influenza | - | - |
Milnacipran | Phase 3 | Depression | - | - |
naproxen | Phase 3 | Osteoarthritis | - | - |
Fentanyl/Morphine | Phase 3 | Sedation | - | - |
Ibuprofen | Phase 3 | Post-surgical Pain Following Extraction of Molar Teeth | - | - |
Temsirolimus | Phase 3 | Renal Cell Carcinoma | - | - |
Etoposide + cisplatin | Phase 3 | Small Cell Lung Carcinoma | - | - |
20-valent pneumococcal conjugate vaccine (20vPnC) | Phase 3 | Pneumococcal Disease | - | - |
Unfractionated Heparin (UFH) | Phase 3 | Deep Vein Thrombosis | - | - |
tolterodine tartrate | Phase 3 | Overactive Bladder | - | - |
Following the planned interim analysis for this study: Avelumab | Phase 3 | Urothelial Cancer | - | - |
bazedoxifene BZA-20 | Phase 3 | Postmenopause | - | - |
rimegepant ODT | Phase 3 | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | - | - |
Rapamune® | Phase 3 | Kidney Disease | - | - |
Pertuzumab | Phase 3 | HER2 Positive Breast Cancer | - | - |
Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine | Phase 3 | Alopecia Areata | - | - |
23-valent Pneumococcal Polysaccharide Vaccine (23vPS) | Phase 3 | HIV Infections | - | - |
Anidulafungin | Phase 3 | Neutropenia | - | - |
adenosine | Phase 3 | Coronary Artery Disease | - | - |
Varenicline Tartarate | Phase 3 | Smoking Cessation | - | - |
Placebp | Phase 3 | Respiratory Syncytial Virus | - | - |
Treatment with Genotropin in different dosages | Phase 3 | Growth Disorder | - | - |
prinomastat | Phase 3 | Brain and Central Nervous System Tumors | - | - |
MEK162 | Phase 3 | Metastatic Colorectal Cancer | - | - |
Abrocitinib | Phase 3 | Atopic Dermatitis | - | - |
5 fluorouracil | Phase 3 | Metastatic Colorectal Cancer | - | - |
LGX818 | Phase 3 | Solid Tumors Harboring a BRAF V600 Mutation | - | - |
vemurafenib | Phase 3 | Melanoma | - | - |
Genotonorm (Somatropin) | Phase 3 | Fetal Growth Retardation | - | - |
Xyntha | Phase 3 | Hemophilia A | - | - |
Zavegepant (BHV-3500) | Phase 3 | Acute Migraine | - | - |
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
SU011248 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
Seasonal Inactivated Influenza Vaccine | Phase 3 | Respiratory Syncytial Virus | - | - |
IV Diclofenac | Phase 3 | Postoperative Pain | - | - |
Piperacillin/Tazobactam (Tazocin) | Phase 3 | Hematologic Neoplasms | - | - |
effervescent ibuprofen tablets | Phase 3 | Pain | - | - |
CP690,550 | Phase 3 | Ulcerative Colitis | - | - |
FOLFIRI regimen | Phase 3 | Colorectal Cancer | - | - |
clarithromycin extended release (ER) | Phase 3 | Pneumonia | - | - |
Xiapex | Phase 3 | Dupuytren's Contracture | - | - |
MTZ | Phase 3 | Complicated Intra-abdominal Infection | - | - |
vaccine-13vPnC | Phase 3 | Pneumococcal Infections | - | - |
PF-04965842 | Phase 3 | Atopic Dermatitis | - | - |
ATM-AVI | Phase 3 | Complicated Intra-Abdominal Infections, cIAIs | - | - |
Recombinant Coagulation Factor IX (BeneFIX) | Phase 3 | Hemophilia B | - | - |
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl | Phase 3 | Encephalitis, Tick-Borne | - | - |
Xalacom | Phase 3 | Glaucoma, Open-Angle | - | - |
Topical IBU twice daily | Phase 3 | Ankle Injuries | - | - |
PLD | Phase 3 | Ovarian Cancer | - | - |
Lorlatinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Ibuprofen Immediate Release/Extended Release Caplet | Phase 3 | Analgesia | - | - |
Clostridium difficile | Phase 3 | Clostridium Difficile Associated Disease | - | - |
PD 0332334 | Phase 3 | Generalized Anxiety Disorder | - | - |
Taxotere® | Phase 3 | Early Breast Cancer | - | - |
PD-0332991 | Phase 3 | Neoplasms | - | - |
UFT | Phase 3 | Colon Cancer | - | - |
PF-07275315 dose 1 | Phase 3 | Moderate to Severe Chronic Obstructive Pulmonary Disease | - | - |
PF-08653944 | Phase 3 | Obesity | - | - |
Leuprolide Open Label | Phase 3 | Hormone Sensitive Prostate Cancer | - | - |
MabThera® | Phase 3 | Follicular Lymphoma | - | - |
MenACWY-CRM | Phase 3 | Meningococcal Vaccine | - | - |
DA-9501 | Phase 3 | Sedation | - | - |
rLP2086 | Phase 3 | Healthy | - | - |
Investigational Medical Product (IMP) administered in parent study | Phase 3 | Osteoarthritis | - | - |
VENLAFAXINE | Phase 3 | Panic Disorders | - | - |
PF-05280586 | Phase 3 | Rheumatoid Arthritis | - | - |
PG4 | Phase 3 | Pneumococcal Disease | - | - |
CE/MPA | Phase 3 | Endometrial Hyperplasia | - | - |
Quadrivalent influenza modRNA vaccine | Phase 3 | Influenza, Human | - | - |
voxelotor | Phase 3 | Sickle Cell Disease | - | - |
Standard Ibuprofen | Phase 3 | Pain | - | - |
23vPS | Phase 3 | Vaccines, Pneumococcal Conjugate Vaccine | - | - |
Zyvox®/Linezolid | Phase 3 | Bacterial Infections | - | - |
Megestrol acetate | Phase 3 | Metastatic Breast Cancer | - | - |
Fragmin/Dalteparin Sodium | Phase 3 | Diabetic Foot Ulcer | - | - |
Rimegepant Orally Disintegrating Tablets (ODT) | Phase 3 | Acute Migraine | - | - |
Lorazepam | Phase 3 | Reflex Epilepsy, Photosensitive | - | - |
RSVpreF MDV | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
TBE vaccine | Phase 3 | Tick-Borne Encephalitis | - | - |
Exubera (inhaled insulin) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Plant cell expressed recombinant glucocerebrosidase (prGCD) | Phase 3 | Gaucher Disease | - | - |
ibuzatrelvir | Phase 3 | COVID-19 Infection | - | - |
Inotuzumab ozogamicin | Phase 3 | ACUTE LYMPHOBLASTIC LEUKEMIA | - | - |
PF-00299804 | Phase 3 | Carcinoma, Non Small Cell Lung | - | - |
7vPnC | Phase 3 | Vaccines, Pneumococcal | - | - |
FLAG (fludarabine, cytarabine and G-CSF) | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
MenABCWY | Phase 3 | Meningococcal Vaccine | - | - |
PF-06462700 | Phase 3 | Aplastic Anemia | - | - |
Multivalent Group B streptococcus vaccine | Phase 3 | Group B Streptococcus Infections | - | - |
Infanrix hexa | Phase 3 | Healthy | - | - |
PF-06651600 Induction Dose | Phase 3 | Alopecia Areata | - | - |
Either switch to oral therapy: of Ciprofloxacin (oral) | Phase 3 | Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis | - | - |
C.difficile vaccine | Phase 3 | Clostridioides Difficile Associated Disease | - | - |
Celebrex | Phase 3 | Osteoarthritis,Knee | - | - |
Abemaciclib | Phase 3 | Breast Cancer | - | - |
or switch to oral therapy:/of sulfamethoxazole/trimethoprim (oral) | Phase 3 | Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis | - | - |
propiverine | Phase 3 | Urinary Bladder, Overactive | - | - |
CAIV-T | Phase 3 | Influenza | - | - |
ATRA plus 6-MP and MTX | Phase 3 | Leukemia, Myelocytic, Acute | - | - |
Sirolimus (Rapamune®) | Phase 3 | Renal Transplant | - | - |
somatrogon | Phase 3 | Growth Hormone Deficiency | - | - |
ampicillin sodium/sulbactam sodium | Phase 3 | Pneumonia, Bacterial | - | - |
(PN-152,243)/PN-196,444 | Phase 3 | Neoplasms | - | - |
Chemotherapy Regimen 1 | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
ALO-02 | Phase 3 | Chronic Pain | - | - |
exemestane (Aromasin) | Phase 3 | Breast Neoplasms | - | - |
somatropin - GH naïve pediatric cohort | Phase 3 | Prader-Willi Syndrome | - | - |
Sirolimus (RAPAMUNE) | Phase 3 | Graft vs Host Disease | - | - |
Irinotecan hydrochloride trihydrate | Phase 3 | Esophageal Cancer | - | - |
Meningococcal group C polysaccharide conjugate vaccine | Phase 3 | Neisseria Meningitidis | - | - |
pantoprazole for approximately 9 weeks | Phase 3 | Gastroesophageal Reflux | - | - |
Methotrexate - Immediate | Phase 3 | Rheumatoid Arthritis | - | - |
Moxifloxacin | Phase 3 | Chronic Bronchitis | - | - |
binodenoson | Phase 3 | Coronary Artery Disease | - | - |
Itraconazole | Phase 3 | Antifungal Prophylaxis of Invasive Fungal Infections | - | - |
bivalent rLP2086 | Phase 3 | Meningococcal Infection | - | - |
Inhaled human insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
relugolix, estradiol, norethindrone acetate | Phase 3 | Endometriosis | - | - |
Pneumo23/Pneumovax | Phase 3 | Rheumatoid Arthritis | - | - |
Hib | Phase 3 | Pneumococcal Infections | - | - |
FDC IBU/APAP | Phase 3 | Pain | - | - |
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC) | Phase 3 | Pneumococcal Disease | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
TS-1 | Phase 3 | Gastric Cancer | - | - |
Axitinib plus Toripalimab | Phase 3 | Renal Cell Carcinoma | - | - |
Avelumab | Phase 3 | Urothelial Cancer | - | - |
FSME-IMMUN NEW | Phase 3 | Tick-borne Encephalitis | - | - |
Methotrexate - Delay | Phase 3 | Rheumatoid Arthritis | - | - |
rFIX-R | Phase 3 | Hemophilia B | - | - |
Sunitinib | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
levoleucovorin | Phase 3 | Colorectal Neoplasms | - | - |
Bleomycin | Phase 3 | Hodgkin Lymphoma | - | - |
tiotropium Respimat® high dose | Phase 3 | Asthma | - | - |
HZ/su VACCINE | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
leucovorin | Phase 3 | Colorectal Carcinoma | - | - |
Vinblastine | Phase 3 | Hodgkin Lymphoma | - | - |
PMI-150 (intranasal ketamine) | Phase 3 | Pain, Postoperative | - | - |
tiotropium Respimat® low dose | Phase 3 | Asthma | - | - |
CCI-779 | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Interferon Alfa and CCI-779 | Phase 3 | Carcinoma, Renal Cell | - | - |
Aromatase Inhibitors | Phase 3 | Metastatic Breast Cancer | - | - |
Maraviroc (UK-427,857) | Phase 3 | HIV Infections | - | - |
amoxicillin/clavulanate postassium (Augmentin ES-600) | Phase 3 | Acute Otitis Media | - | - |
Advanced therapy only without dietary intervention | Phase 3 | Ulcerative Colitis | - | - |
Haematopoietic growth factor | Phase 3 | Hodgkin Lymphoma | - | - |
Chemotherapy Regimen 2 | Phase 3 | Carcinoma | - | - |
Fulvestrant Injectable Product | Phase 3 | Metastatic Breast Cancer | - | - |
Optimized Background Therapy | Phase 3 | HIV Infections | - | - |
azithromycin SR | Phase 3 | Acute Otitis Media | - | - |
Dicloxacillin | Phase 3 | Bacterial Infections | - | - |
Oxacillin | Phase 3 | Bacterial Infections | - | - |
Ibuprofen/acetaminophen | Phase 3 | Pain | - | - |
Donepezil (Aricept) | Phase 3 | Alzheimer Disease | - | - |
Lorlatanib | Phase 3 | Advanced Malignancies | - | - |
Utomilumab | Phase 3 | Stage III Breast Cancer | - | - |
PF-06651600 Maintenance Dose #3 | Phase 3 | Alopecia Areata | - | - |
Standard-of-Care plus Dexmedetomidine | Phase 3 | Endotracheal Intubation | - | - |
RSVpreF (Group 2) | Phase 3 | RSV | - | - |
diphtheria, tetanus, and acellular pertussis vaccine (DTaP) | Phase 3 | Healthy Subjects | - | - |
PF-06651600 Maintenance Dose #1 | Phase 3 | Alopecia Areata | - | - |
RSVpreF (Group 3) | Phase 3 | RSV | - | - |
SABER-Bupivacaine | Phase 3 | Postoperative Pain | - | - |
PF04965842 | Phase 3 | Atopic Dermatitis | - | - |
recombinant human growth hormone | Phase 3 | Abdominal Obesity | - | - |
PF-06651600 Maintenance Dose #2 | Phase 3 | Alopecia Areata | - | - |
CMP 001 | Phase 3 | Advanced Malignancies | - | - |
PF04518600 | Phase 3 | Advanced Malignancies | - | - |
BNT162b2 | Phase 3 | SARS-CoV-2 Infection | - | - |
brentuximab vedotin | Phase 3 | Lymphoma, B-Cell | - | - |
Ketamine | Phase 3 | Chronic Daily Headache | - | - |
DVS-233 SR (desvenlafaxine sustained release) | Phase 3 | Major Depressive Disorder | - | - |
Insulin Lispro | Phase 3 | Diabetes Mellitus | - | - |
Cyclosporine A | Phase 3 | Renal Transplantation | - | - |
13 valent pneumococcal conjugate vaccine with Polysorbate 80 | Phase 3 | Vaccines, Pneumococcal | - | - |
Meropenem | Phase 3 | Complicated Intra-abdominal Infections | - | - |
MET097 | Phase 3 | Obesity | - | - |
RSVpreF (Group 1) | Phase 3 | RSV | - | - |
Imipenem-cilastatin | Phase 3 | Skin Infection | - | - |
Diclofenac | Phase 3 | Spondylitis, Ankylosing | - | - |
Pediacel | Phase 3 | Vaccines, Pneumococcal | - | - |
Pemetrexed/Cisplatin | Phase 3 | NSCLC (Non-small Cell Lung Cancer) | - | - |
Conventional amphotericin B | Phase 3 | Candidiasis | - | - |
bazedoxifene/conjugated estrogens | Phase 3 | Menopause | - | - |
azithromycin SR (Zithromax; compound: CP-62,993) | Phase 3 | Maxillary Sinusitis | - | - |
desvenlafaxine succinate (DVS) SR | Phase 3 | Vasomotor Symptoms | - | - |
PF-06823859 | Phase 3 | Myositis | - | - |
axitinib | Phase 3 | Carcinoma, Non-Small Cell Lung | - | - |
Ritlecitinib | Phase 3 | Stable Nonsegmental Vitiligo | - | - |
Nonacog alfa | Phase 3 | Hemophilia B | - | - |
Novel Ibuprofen | Phase 3 | Pain | - | - |
AG-013736 | Phase 3 | Carcinoma, Pancreatic Ductal | - | - |
Epoetin Hospira Arm | Phase 3 | Chronic Kidney Disease (CKD) | - | - |
Imipenem | Phase 3 | Bacterial Pneumonia | - | - |
marstacimab | Phase 3 | Hemophilia A | - | - |
Bosutinib | Phase 3 | Polycystic Kidney, Autosomal Dominant | - | - |
Inhaled Insulin | Phase 3 | Asthma | - | - |
Rimegepant | Phase 3 | Acute Migraine | - | - |
Bazedoxifene/Conjugate Estrogens (CE) | Phase 3 | Endometrial Hyperplasia | - | - |
7-valent Pneumococcal Conjugate Vaccine | Phase 3 | Pneumococcal Infection | - | - |
Modified Bolus 5-FU/LV with Irinotecan | Phase 3 | Colorectal Neoplasms | - | - |
varenicline (CP-526,555) | Phase 3 | Smoking Cessation | - | - |
Tigecycline | Phase 3 | Gram-Positive Bacterial Infections | - | - |
fesoterodine fumarate | Phase 3 | Overactive Bladder | - | - |
SPM 907 | Phase 3 | Overactive Bladder Syndrome | - | - |
Somatropin | Phase 3 | Endocrine System Diseases | - | - |
Parecoxib Sodium/Valdecoxib | Phase 3 | Pain | - | - |
Palbociclib | Phase 3 | Breast Cancer | - | - |
DVS-233 | Phase 3 | Menopause | - | - |
Tisotumab Vedotin | Phase 3 | Cervical Cancer | - | - |
13-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Vaccines | - | - |
AN2690 Topical | Phase 3 | Onychomycosis of Toenails | - | - |
AN2728 Topical | Phase 3 | Dermatitis, Atopic | - | - |
levonorgestrel/ethinyl estradiol | Phase 3 | Menstruation Disturbances | - | - |
Ritlecitinib higher dose | Phase 3 | Severe Alopecia Areata | - | - |
PF-07321332 | Phase 3 | COVID-19 | - | - |
Pentavac | Phase 3 | Vaccines, Pneumococcal | - | - |
Encorafenib | Phase 3 | BRAF V600E-mutant Metastatic Colorectal Cancer | - | - |
20-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Disease | - | - |
Talazoparib with enzalutamide | Phase 3 | mCRPC | - | - |
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT) | Phase 3 | Meningitis, Meningococcal | - | - |
Genotropin | Phase 3 | Idiopathic Short Stature | - | - |
bapineuzumab | Phase 3 | Alzheimer Disease | - | - |
DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa | Phase 3 | Allogeneic Haematopoietic Stem Cell Transplantation | - | - |
Zavegepant | Phase 3 | Migraine | - | - |
[S,S]-Reboxetine | Phase 3 | Fibromyalgia | - | - |
PF-06651600 | Phase 3 | Active Non-segmental Vitiligo | - | - |
Taliglucerase alfa | Phase 3 | Gaucher Disease | - | - |
PF-06410293 | Phase 3 | Rheumatoid Arthritis | - | - |
linezolid | Phase 3 | Febrile Neutropenia | - | - |
Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7) | Phase 3 | Neisseria Meningitidis (Bacterial Meningitis) | - | - |
Desvenlafaxine succinate sustained-release (DVS SR) | Phase 3 | Depression | - | - |
Epirubicin with Cyclophosphamide, followed by a Taxane | Phase 3 | Adenocarcinoma | - | - |
Ceftazidime-avibactam | Phase 3 | Complicated Intra-abdominal Infection | - | - |
talazoparib plus enzalutamide | Phase 3 | Prostate Cancer | - | - |
Ibuprofen/Caffeine | Phase 3 | Pain | - | - |
PF-06947386 | Phase 3 | Complicated Intra-abdominal Infection | - | - |
tucatinib | Phase 3 | HER2-positive Breast Cancer | - | - |
CP-690,550 | Phase 3 | Crohn's Disease | - | - |
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) | Phase 3 | Encephalitis, Tick-borne | - | - |
Bococizumab (PF-04950615;RN316) | Phase 3 | Hyperlipidemia | - | - |
ponsegromab | Phase 3 | Non-small Cell Lung Cancer | - | - |
Dexmedetomidine | Phase 3 | Sedation | - | - |
DVS-233 SR | Phase 3 | Major Depressive Disorder | - | - |
Dacomitinib (PF-00299804) | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Genotropin (PN-180,307) Somatropin | Phase 3 | Infant, Small for Gestational Age | - | - |
sumanirole | Phase 3 | Parkinson Disease | - | - |
UK-390,957 | Phase 3 | Ejaculation | - | - |
torcetrapib/atorvastatin | Phase 3 | Hyperlipidemia | - | - |
dalteparin | Phase 3 | Venous Thromboembolism | - | - |
RSVpreF | Phase 3 | RSV Infection | - | - |
disitamab vedotin | Phase 3 | Urothelial Carcinoma | - | - |
Fesoterodine | Phase 3 | Overactive Bladder Syndrome | - | - |
Nimenrix | Phase 3 | Meningococcal Vaccine | - | - |
7-Valent Pneumococcal Conjugate Vaccine (7vPnC) | Phase 3 | Healthy Subjects | - | - |
Meningococcal vaccine GSK134612 | Phase 3 | Infections, Meningococcal | - | - |
13-valent pneumococcal conjugate vaccine (13vPnC) | Phase 3 | Healthy Subjects | - | - |
Moroctocog alfa (AF-CC) | Phase 3 | Hemophilia A | - | - |
lecozotan SR (SRA-333) | Phase 3 | Alzheimer Disease | - | - |
7 valent pneumococcal conjugate vaccine | Phase 3 | Vaccines, Pneumococcal | - | - |
Inhaled human insulin (EXUBERA™) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Tolterodine ER | Phase 3 | Overactive Bladder | - | - |
Fragmin | Phase 3 | Diabetic Foot Ulcer | - | - |
Tafamidis | Phase 3 | Transthyretin (TTR) Amyloid Cardiomyopathy | - | - |
Interferon-alfa | Phase 3 | Carcinoma, Renal Cell | - | - |
tanezumab | Phase 3 | Arthritis | - | - |
13vPnC | Phase 3 | Vaccines, Pneumococcal Conjugate Vaccine | - | - |
Rifabutin | Phase 3 | Mycoses | - | - |
endocrine-modulating drug therapy | Phase 3 | Prostate Cancer | - | - |
Ibuprofen Sodium | Phase 3 | Pain | - | - |
ceftazidim-avibactam (CAZ-AVI, experimental product) | Phase 3 | Nosocomial Pneumonia (NP) | - | - |
leflunomide | Phase 3 | Prostate Cancer | - | - |
Cyclosporin or tacrolimus | Phase 3 | Graft Rejection | - | - |
Edotecarin | Phase 3 | Breast Neoplasms | - | - |
Ceftaroline fosamil | Phase 3 | Complicated Skin and Soft Tissue Infection | - | - |
Sasanlimab | Phase 2 | Urothelial Carcinoma Bladder | - | - |
DTP/Hib | Phase 2 | Meningitis, Meningococcal | - | - |
NMDA Antagonist, CP-101,606 (traxoprodil) | Phase 2 | Depressive Disorder, Major | - | - |
MultiStem high dose | Phase 2 | Colitis, Ulcerative | - | - |
maraviroc (Selzentry) | Phase 2 | HIV Infections | - | - |
Vaccine Candidate #1 | Phase 2 | Healthy Adults | - | - |
AN2898 | Phase 2 | Dermatitis, Atopic | - | - |
PF-08653945 | Phase 2 | Overweight | - | - |
Dorzolamide | Phase 2 | Glaucoma | - | - |
PF-08049820 | Phase 2 | Atopic Dermatitis | - | - |
PF-06826647 | Phase 2 | Psoriasis | - | - |
Allegra | Phase 2 | Allergic Rhinitis | - | - |
Letrozole/Temsirolimus (CCI-779) | Phase 2 | Breast Neoplasms | - | - |
AG-013726 | Phase 2 | Colorectal Neoplasms | - | - |
EXC 001 (currently called PF-06473871) | Phase 2 | Reduction in Severity of Skin Scarring | - | - |
Carfilzomib, proteasome inhibitor; intravenous | Phase 2 | Advanced Multiple Myeloma | - | - |
PF-06835919 | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
PF-07850327, ARV-471, vepdegestrant | Phase 2 | Locally Advanced or Metastatic ER+ HER2- Breast Cancer | - | - |
CP-690-550 | Phase 2 | Arthritis, Rheumatoid | - | - |
SU-011,248 | Phase 2 | Kidney Neoplasms | - | - |
Sunitinib (SU011248) | Phase 2 | Liver Neoplasms | - | - |
Tygacil | Phase 2 | Bacterial Infections | - | - |
tacedinaline | Phase 2 | Pancreatic Cancer | - | - |
Multivalent Pneumococcal Vaccine - Formulation 1 | Phase 2 | Pneumococcal Disease | - | - |
SU011248, Sutent | Phase 2 | Papillary Thyroid Cancer | - | - |
Multivalent Pneumococcal Vaccine - Formulation 2 | Phase 2 | Pneumococcal Disease | - | - |
PF-04217329 - Lowest Dose | Phase 2 | Primary Open-Angle Glaucoma | - | - |
(Part C) MET097 | Phase 2 | Obesity and Overweight | - | - |
inotuzumab ozogamicin (CMC-544) | Phase 2 | Lymphoma, B-Cell | - | - |
PF-07104091 monotherapy dose escalation | Phase 2 | Small Cell Lung Cancer | - | - |
NR2B NMDA Antagonist CP-101,606 (traxoprodil) | Phase 2 | Parkinson's Disease | - | - |
Capecitabine tablets | Phase 2 | Leptomeningeal Metastasis | - | - |
PF-06291874 | Phase 2 | Diabetes Mellitus, Type II | - | - |
Bupivacaine TTS (Bupivacaine Patch) | Phase 2 | Chronic Low Back Pain | - | - |
MRE0094 | Phase 2 | Foot Ulcer, Diabetic | - | - |
(CP-690,550) Tofacitinib | Phase 2 | Plaque Psoriasis | - | - |
PF-03654746 | Phase 2 | Excessive Daytime Sleepiness | - | - |
PF-06882961 | Phase 2 | Diabetes | - | - |
PF-00489791 | Phase 2 | Diabetic Nephropathies | - | - |
PF-00217830 | Phase 2 | Schizophrenia | - | - |
UK-453, 061 | Phase 2 | HIV-1 | - | - |
EKB-569 | Phase 2 | Colorectal Neoplasms | - | - |
Multivalent Pneumococcal Vaccine - Formulation 3 | Phase 2 | Pneumococcal Disease | - | - |
ARRY-502, CRTh2 antagonist; oral | Phase 2 | Asthma | - | - |
Levonorgestrel | Phase 2 | Ovulation | - | - |
Formulation A | Phase 2 | Respiratory Tract Infections | - | - |
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection | Phase 2 | Shingles | - | - |
CPG 7909 Injection | Phase 2 | Carcinoma, Melanoma | - | - |
Low dose cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
Multivalent Pneumococcal Vaccine - Formulation 4 | Phase 2 | Pneumococcal Disease | - | - |
Phase Ib ARRY-614 + nivolumab+ipilimumab | Phase 2 | Renal Cell Carcinoma | - | - |
Multivalent | Phase 2 | Pneumococcal Infections | - | - |
Filibuvir | Phase 2 | Hepatitis | - | - |
CP-690,550 + methotrexate | Phase 2 | Rheumatoid Arthritis | - | - |
Samuraciclib | Phase 2 | Breast Cancer | - | - |
AN2728 | Phase 2 | Psoriasis | - | - |
PF-06823859 low | Phase 2 | Dermatomyositis | - | - |
PF-04494700 (TTP488) | Phase 2 | Diabetic Nephropathy | - | - |
QS-21 | Phase 2 | Alzheimer Disease | - | - |
Selenomethionine (SLM) | Phase 2 | Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) | - | - |
PF-04937319 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
BGJ398 | Phase 2 | Melanoma | - | - |
ARRY-438162, MEK inhibitor; oral | Phase 2 | Rheumatoid Arthritis | - | - |
ACC-001 | Phase 2 | Alzheimer's Disease | - | - |
FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil) | Phase 2 | Unresectable or Metastatic Colorectal Cancer | - | - |
PF-05089771 | Phase 2 | Postoperative Dental Pain | - | - |
SKI-606 (Bosutinib) | Phase 2 | Chronic Myelogenous Leukemia | - | - |
PF-00610355 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
PF-04217329 - High Dose | Phase 2 | Primary Open-Angle Glaucoma | - | - |
PBO | Phase 2 | Hypercholesterolemia | - | - |
PF-299804 (Dacomitinib) | Phase 2 | Glioblastoma | - | - |
PF-04136309 | Phase 2 | Osteoarthritis, Knee | - | - |
vepdegestrant | Phase 2 | Breast Cancer | - | - |
PF-04236921 | Phase 2 | Crohn's Disease | - | - |
Pentostatin | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Meningococcal C | Phase 2 | Meningitis, Meningococcal | - | - |
PD 0348292 | Phase 2 | Venous Thrombosis | - | - |
PF-06835919 Low Dose | Phase 2 | Non-alcoholic Fatty Liver Disease | - | - |
Axitinib Oral Tablet | Phase 2 | Renal Cell Carcinoma | - | - |
PF-04457845 | Phase 2 | Osteoarthritis, Knee | - | - |
BAT | Phase 2 | Gram-negative Bacterial Infections | - | - |
Anrukinzumab | Phase 2 | Colitis, Ulcerative | - | - |
PH-797804 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
UK-369,003 | Phase 2 | Prostatic Hyperplasia | - | - |
Tucatinib in Combination of Oral VP16 and trastuzumab | Phase 2 | HER2-positive Breast Cancer | - | - |
Phase II ARRY-614 + nivolumab+ipilimumab (melanoma) | Phase 2 | Renal Cell Carcinoma | - | - |
Taxotere (docetaxel) | Phase 2 | Prostatic Neoplasms | - | - |
PF-07868489 | Phase 2 | Pulmonary Arterial Hypertension | - | - |
Nicotine Adaptive Protocol | Phase 2 | Nicotine Dependence | - | - |
High Dose PF-07328948 | Phase 2 | Heart Failure | - | - |
exemestane (Aromasin®) | Phase 2 | Breast Neoplasms | - | - |
SS-RBX | Phase 2 | Urinary Incontinence, Stress | - | - |
PF-06650833 | Phase 2 | Acne Inversa | - | - |
Bosutinib (Phase 2 part) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
PF - 00610355 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Tucatinib (ONT-380) | Phase 2 | Metastatic Breast Cancer ( HER2 Negative) | - | - |
Elranatamab (PF-06863135) | Phase 2 | Multiple Myeloma | - | - |
PF-00734200 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Anti-Beta Interferon (PF-06823859) | Phase 2 | Dermatomyositis | - | - |
mPnC candidate | Phase 2 | Healthy Participants | - | - |
PF-07220060 + PF-07104091 combination dose escalation | Phase 2 | Breast Cancer | - | - |
EXC 001 | Phase 2 | Scar Prevention | - | - |
SAM-531 | Phase 2 | Alzheimer Disease | - | - |
Trastuzumab plus Pertuzumab | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
mIRV | Phase 2 | Influenza, Human | - | - |
PF- 00610355 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor inhibitor | Phase 2 | Kidney Neoplasms | - | - |
CP-778,875 | Phase 2 | Dyslipidemia | - | - |
Atomoxetine | Phase 2 | Attention Deficit Disorder With Hyperactivity | - | - |
CP-533, 536 | Phase 2 | Tibial Fractures | - | - |
SBI-087 | Phase 2 | Active Rheumatoid Arthritis | - | - |
Methotrexate plus ERB-041 | Phase 2 | Rheumatoid Arthritis | - | - |
PF-04494700 - Low Dose Arm | Phase 2 | Alzheimer Disease | - | - |
RN624 (PF-04383119) | Phase 2 | Osteoarthritis | - | - |
Elranatamab + Nirogacestat | Phase 2 | Multiple Myeloma | - | - |
rhBMP-2/CPM | Phase 2 | Fractures | - | - |
ACC-001 + QS21 | Phase 2 | Alzheimer Disease | - | - |
CE-224,535 | Phase 2 | Arthritis, Rheumatoid | - | - |
BNT162b2 (Omi XBB.1.5)/RIV | Phase 2 | Influenza, Human | - | - |
Hormone therapy | Phase 2 | Metastatic Breast Cancer With a Isolated Brain Progression | - | - |
MultiStem low dose | Phase 2 | Colitis, Ulcerative | - | - |
Doxil | Phase 2 | Breast Cancer | - | - |
Doxorubicin Hydrochloride | Phase 2 | Hodgkin Lymphoma | - | - |
Sitexsentin sodium | Phase 2 | Diastolic Heart Failure | - | - |
SPK-9001 | Phase 2 | Hemophilia B | - | - |
CP-866,087 | Phase 2 | Alcoholism | - | - |
Tucatinib Oral Tablet | Phase 2 | Leptomeningeal Metastasis | - | - |
AG013736 | Phase 2 | Thyroid Neoplasms | - | - |
PF-07275315 | Phase 2 | Asthma | - | - |
ARRY-371797, p38 inhibitor; oral | Phase 2 | LMNA-Related Dilated Cardiomyopathy | - | - |
Phase II ARRY-614 + nivolumab | Phase 2 | Renal Cell Carcinoma | - | - |
CP-751,871 | Phase 2 | Prostatic Neoplasms | - | - |
CPG10101 | Phase 2 | Hepatitis, Chronic Active | - | - |
PF-06372865 | Phase 2 | Chronic Low Back Pain | - | - |
CMC-544 (Inotuzumab Ozogamycin) | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
RSV Vaccine | Phase 2 | Respiratory Tract Infection | - | - |
Elrantamab | Phase 2 | Multiple Myeloma | - | - |
PF-04383119 (tanezumab) | Phase 2 | Osteoarthritis, Knee | - | - |
Investigational drug | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
SU011248 capsule | Phase 2 | Carcinoma, Renal Cell | - | - |
interferon beta treatment to add-on atorvastatin treatment | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
Dacomitinib | Phase 2 | Non-small Cell Lung Cancer | - | - |
PF-00232798 | Phase 2 | HIV | - | - |
SB-525 (PF-07055480) | Phase 2 | Hemophilia A | - | - |
PF-07817883 | Phase 2 | SARS-CoV-2 Infection | - | - |
Belinostat | Phase 2 | Metastatic Uveal Melanoma | - | - |
Medium Dose PF-07328948 | Phase 2 | Heart Failure | - | - |
PF06700841 | Phase 2 | Active Non-segmental Vitiligo | - | - |
ILV-094 | Phase 2 | Rheumatoid Arthritis | - | - |
pneumococcal polysaccharide and protein conjugate vaccines | Phase 2 | Pneumococcal Infections | - | - |
Crizotinib (PF-02341066) | Phase 2 | Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | - | - |
Paclitaxel,Gemcitabine,Sunitinib | Phase 2 | Breast Cancer | - | - |
Low Dose PF-07328948 | Phase 2 | Heart Failure | - | - |
SU011248 (sunitinib) | Phase 2 | Carcinoma, Renal Cell Metastasis | - | - |
Linezolid (TIW) | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
Rapamune® (Sirolimus) | Phase 2 | Kidney Transplantation | - | - |
SD-6010 | Phase 2 | Osteoarthritis | - | - |
CP-690,550 Ointment 1 | Phase 2 | Psoriasis | - | - |
AN2690 | Phase 2 | Onychomycosis | - | - |
Gardasil | Phase 2 | Vaccines | - | - |
Sertraline and Elzasonan Combination | Phase 2 | Depressive Disorder, Major | - | - |
Ponezumab | Phase 2 | Cerebral Amyloid Angiopathy | - | - |
PF-00868554 | Phase 2 | Hepatitis C | - | - |
maplirpacept (PF-07901801) | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
Vaccine | Phase 2 | Meningococcal Vaccine | - | - |
bIRV AA | Phase 2 | Influenza, Human | - | - |
Licensed pediatric hepatits A vaccine | Phase 2 | MENINGOCOCCAL INFECTION | - | - |
SU014813 | Phase 2 | Breast Neoplasms | - | - |
Tdap | Phase 2 | Pneumococcal Infections | - | - |
rLP2086 + MCV4 + Tdap | Phase 2 | Vaccines | - | - |
Temsirolimus and Sorafenib | Phase 2 | Thyroid Cancer | - | - |
Ceftazidime -avibactam | Phase 2 | Complicated Urinary Tract Infections | - | - |
Atovaquone | Phase 2 | Bacterial Infections | - | - |
(CP-6890,550) Tofacitinib | Phase 2 | Plaque Psoriasis | - | - |
CP-547,632 | Phase 2 | Ovarian Neoplasms | - | - |
Esreboxetine | Phase 2 | Fibromyalgia | - | - |
UK-453,061 | Phase 2 | HIV-1 | - | - |
PF-06473871 | Phase 2 | Reduction of Hypertrophic Skin Scarring | - | - |
15-valent pneumococcal conjugate vaccine (PCV15) | Phase 2 | Pneumococcal Disease | - | - |
untreated to atorvastatin treatment | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
Sulfamethoxazole-Trimethoprim | Phase 2 | Bacterial Infections | - | - |
RIV | Phase 2 | Influenza, Human | - | - |
rLP2086 and Gardasil | Phase 2 | Vaccines | - | - |
Sunitinib Malate Continuous Daily Dosing | Phase 2 | Carcinoma, Renal Cell | - | - |
PF-00446687 | Phase 2 | Erectile Dysfunction | - | - |
NXL104/ceftazidime | Phase 2 | Complicated Urinary Tract Infection | - | - |
Duavee | Phase 2 | Breast Cancer | - | - |
ERB-041 | Phase 2 | Endometriosis | - | - |
bIRV AB | Phase 2 | Influenza, Human | - | - |
AG-013736 (Axitinib) | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
temsirolimus plus liposomal doxorubicin | Phase 2 | Sarcoma | - | - |
LEE011 | Phase 2 | Locally Advanced or Metastatic NRAS Mutant Melanoma | - | - |
Macugen ™ (pegaptanib sodium injection) | Phase 2 | Macular Degeneration | - | - |
7-valent pneumococcal conjugate vaccine (vaccine) | Phase 2 | HIV Infections | - | - |
PF-07976016 | Phase 2 | Obesity | - | - |
qIRV | Phase 2 | Influenza, Human | - | - |
PF-04494700 | Phase 2 | Alzheimer's Disease | - | - |
CP-751, 871 | Phase 2 | Colorectal Neoplasm | - | - |
PF-610,355 | Phase 2 | Asthma | - | - |
CP-690,550 Eye drops | Phase 2 | Dry Eye Syndromes | - | - |
CP-690,550 Ointment 2 | Phase 2 | Psoriasis | - | - |
Tofimilast | Phase 2 | Asthma | - | - |
Tiotropium bromide | Phase 2 | Asthma | - | - |
Tick-borne Encephalitis Vaccine | Phase 2 | Tick-borne Encephalitis | - | - |
PF-02545920 | Phase 2 | Huntington's Disease | - | - |
Sumatriptan | Phase 2 | Migraine | - | - |
bIRV BB | Phase 2 | Influenza, Human | - | - |
PF-04991532 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
ceftazidime/NXL104 + metronidazole | Phase 2 | Complicated Intra-abdominal Infections | - | - |
INC280 | Phase 2 | Melanoma | - | - |
MAC-321 | Phase 2 | Colorectal Neoplasms | - | - |
Combination [RSVpreF+BNTb162b2] | Phase 2 | Healthy Participants | - | - |
PD-0299685 | Phase 2 | Hot Flashes | - | - |
tiotropium-bromide | Phase 2 | Asthma | - | - |
Dexmedetomidine, midazolam; fentanyl | Phase 2 | Intubated and Mechanically Ventilated Pediatric Subjects | - | - |
CP- 690 550 | Phase 2 | Ulcerative Colitis | - | - |
PF-04191834 | Phase 2 | Asthma | - | - |
PF-04171327 | Phase 2 | Rheumatoid Arthritis | - | - |
Gemtuzumab Ozogamicin (GO) | Phase 2 | Acute Myeloid Leukemia | - | - |
23-valent pneumococcal conjugate vaccine (vaccine) | Phase 2 | HIV Infections | - | - |
Anti-NGF AB | Phase 2 | Neoplasms | - | - |
Mylotarg (gemtuzumab ozogamicin) Injection | Phase 2 | Acute Myelogenous Leukemia | - | - |
ACC-001 (vanutide cridificar) | Phase 2 | Alzheimer's Disease | - | - |
PD 0299685 | Phase 2 | Interstitial Cystitis | - | - |
Elranatamab injection | Phase 2 | Refractory Multiple Myeloma | - | - |
PF-06882961 (Cohorts 1 and 2) | Phase 2 | Obesity | - | - |
Bazedoxifene | Phase 2 | Postmenopausal Osteoporosis | - | - |
PF-05221304 | Phase 2 | Nonalcoholic Fatty Liver Disease | - | - |
ARRY-520, KSP(Eg5) inhibitor; intravenous | Phase 2 | Multiple Myeloma | - | - |
ALO-01 | Phase 2 | Healthy | - | - |
FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]) | Phase 2 | Colorectal Neoplasms | - | - |
Capravirine | Phase 2 | Human Immunodeficiency Virus | - | - |
Bivalent rLP2086 Vaccine | Phase 2 | MENINGOCOCCAL INFECTION | - | - |
Prevenar13 | Phase 2 | IgG Deficiency | - | - |
TMI-005 | Phase 2 | Rheumatoid Arthritis | - | - |
Combination 1 | Phase 2 | Carcinoma, Renal Cell | - | - |
BNT162b2 (Omi XBB.1.5) | Phase 2 | Influenza, Human | - | - |
Influenza ModRNA Vaccine | Phase 2 | Influenza, Human | - | - |
ATM-AVI Single Dose, Cohorts 1-4 | Phase 2 | Gram-negative Bacterial Infection | - | - |
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6) | Phase 2 | Group B Streptococcal Infections | - | - |
Investigational Influenza Vaccine | Phase 2 | Influenza | - | - |
meningococcal B rLP2086 vaccine | Phase 2 | Meningitis, Meningococcal | - | - |
Anti-OX40 Antibody PF-04518600 | Phase 2 | Stage III Breast Cancer | - | - |
FUFA | Phase 2 | Colorectal Cancer | - | - |
PF-04217329 - Low Dose | Phase 2 | Primary Open-Angle Glaucoma | - | - |
PF-04217329 - High Middle Dose | Phase 2 | Primary Open-Angle Glaucoma | - | - |
PF-07264660 | Phase 2 | Atopic Dermatitis | - | - |
PF-3512676 | Phase 2 | Lymphoma, T-Cell, Cutaneous | - | - |
PF-00592379 | Phase 2 | Impotence | - | - |
sulopenem and PF-03709270 | Phase 2 | Pneumonia, Bacterial | - | - |
PF-4217329 - Highest Dose | Phase 2 | Primary Open-Angle Glaucoma | - | - |
PF-07038124 ointment | Phase 2 | Atopic Dermatitis | - | - |
Rapamycin | Phase 2 | Nonmalignant Neoplasm | - | - |
WNT974 | Phase 2 | Metastatic Colorectal Cancer | - | - |
sunitinib malate dose escalation | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Tetanus, diphtheria, and acellular pertussis vaccine | Phase 2 | Group B Streptococcus Infections | - | - |
PF-04447943 | Phase 2 | Alzheimer's Disease | - | - |
PD 0332991 | Phase 2 | Breast Cancer | - | - |
PF-06835375 | Phase 2 | Primary Immune Thrombocytopenia | - | - |
Torisel | Phase 2 | Adenocarcinoma | - | - |
meningococcal B rLP2086 vaccine candidate | Phase 2 | Meningitis, Meningococcal | - | - |
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab | Phase 2 | Lung Cancer (NSCLC) | - | - |
ARRY-334543, EGFR/ErbB2 inhibitor; oral | Phase 2 | Advanced Cancer | - | - |
Recombinant Human Interleukin-11 (rhIL-11) | Phase 2 | Crohn Disease | - | - |
sitaxsentan (Thelin) | Phase 2 | Cardiac Surgery Subjects | - | - |
Bosutinib (Phase 1 part) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
C. difficile vaccine (previously studied formulation) | Phase 2 | Clostridoides Difficile Associated Disease | - | - |
PF-07038124 | Phase 2 | Atopic Dermatitis | - | - |
Kaletra | Phase 2 | HIV Infections | - | - |
PF-05221304 Monotherapy | Phase 2 | Non-Alcoholic Fatty Liver Disease (NAFLD) | - | - |
Alclometasone cream | Phase 2 | Non Small Cell Lung Cancer (NSCLC) | - | - |
852A | Phase 2 | Melanoma | - | - |
PD 0200390 | Phase 2 | Nonrestorative Sleep | - | - |
PF-03654764 | Phase 2 | Allergic Rhinitis | - | - |
PD0332991 | Phase 2 | Breast Neoplasms | - | - |
MET233 and MET097 | Phase 2 | Obesity and Obesity-related Medical Conditions | - | - |
Vemurafenib plus Cobimetinib | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
vabicaserin | Phase 2 | Schizophrenia | - | - |
CI-1033 | Phase 2 | Breast Neoplasms | - | - |
CE-326,597 | Phase 2 | Weight Management | - | - |
PF00299804 | Phase 2 | Advanced Gastric Cancer | - | - |
Repevax | Phase 2 | Meningococcal Vaccine | - | - |
CI 1033 | Phase 2 | Lung Neoplasms | - | - |
PF-04383119 | Phase 2 | Cystitis, Interstitial | - | - |
Open | Phase 2 | Chronic Kidney Disease | - | - |
Guaifenesin | Phase 2 | Chronic Rhinitis | - | - |
PF-06838435 (formerly SPK-9001) | Phase 2 | Hemophilia B | - | - |
RN624 | Phase 2 | Neuralgia, Postherpetic | - | - |
PD-217,014 | Phase 2 | Irritable Bowel Syndrome | - | - |
HSP-130 | Phase 2 | Non-metastatic Breast Cancer | - | - |
Axitinib [AG-013736] | Phase 2 | Melanoma | - | - |
IMA-638 | Phase 2 | Asthma | - | - |
PF-03446962 | Phase 2 | Malignant Pleural Mesothelioma | - | - |
CP-526,555 (varenicline) | Phase 2 | Smoking Cessation | - | - |
Tolterodine & Pregabalin | Phase 2 | Overactive Bladder | - | - |
MET233 | Phase 2 | Obesity and Overweight | - | - |
SCA-136 | Phase 2 | Schizophrenia | - | - |
ACC-001/QS-21 | Phase 2 | Alzheimer's Disease | - | - |
Tisotumab vedotin (HuMax-TF-ADC) | Phase 2 | Ovary Cancer | - | - |
Tamsulosin | Phase 2 | Prostatic Hyperplasia | - | - |
PF-06835919 High Dose | Phase 2 | Non-alcoholic Fatty Liver Disease | - | - |
Creatine | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
IMA-638 is a biologic | Phase 2 | Asthma | - | - |
CPG 7909 | Phase 2 | Carcinoma, Non-Small Cell Lung | - | - |
Vupanorsen | Phase 2 | Dyslipidemias | - | - |
Staphylococcus aureus 4-antigen vaccine | Phase 2 | Staphylococcal Infections | - | - |
SGN-35 | Phase 2 | CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma | - | - |
Herceptin® | Phase 2 | Carcinoma, Metastatic Breast | - | - |
PF-07220060 CDK4 inhibitor | Phase 2 | Advanced or Metastatic Breast Cancer | - | - |
Peg-Intron | Phase 2 | Hepatitis C | - | - |
PF-06700841 | Phase 2 | Psoriatic Arthritis | - | - |
Filanesib, KSP (Eg5) inhibitor; intravenous | Phase 2 | Advanced Multiple Myeloma | - | - |
Pediatric HAV vaccine | Phase 2 | Meningococcal B Disease | - | - |
Gemcitabine, nucleoside analogue; intravenous | Phase 2 | Advanced Cancer | - | - |
RV521 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
Naproxen + PH-797804 | Phase 2 | Osteoarthritis | - | - |
Irinotecan plus capecitabine | Phase 2 | Carcinoma, Hepatocellular | - | - |
Tasocitinib plus Methotrexate | Phase 2 | Rheumatoid Arthritis | - | - |
FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]) | Phase 2 | Colorectal Neoplasms | - | - |
PF-04236921 SC injection | Phase 2 | Crohn's Disease | - | - |
PF-04634817 | Phase 2 | Diabetic Nephropathy | - | - |
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) | Phase 2 | Depression | - | - |
ACC-001 + QS-21 | Phase 2 | Alzheimer Disease | - | - |
cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
ARRY-371797, p38 inhibitor, oral | Phase 2 | LMNA-Related Dilated Cardiomyopathy | - | - |
PELITREXOL/AG-2037 | Phase 2 | Colorectal Neoplasms | - | - |
Phase Ib ARRY-614 + nivolumab | Phase 2 | Renal Cell Carcinoma | - | - |
Combination Agent 1 | Phase 2 | Advanced/Metastatic Non-Small Cell Lung Cancer | - | - |
Phase II ARRY-614 + nivolumab+ipilimumab (RCC) | Phase 2 | Renal Cell Carcinoma | - | - |
UK0369,003 | Phase 2 | Impotence | - | - |
PF-04449913 | Phase 2 | Acute Myeloid Leukemia | - | - |
PF-04217329 | Phase 2 | Glaucoma, Open-Angle | - | - |
Statin | Phase 2 | Hypercholesterolemia | - | - |
lecozotan SR | Phase 2 | Alzheimer Disease | - | - |
Tucatinib in Combination with Palbociclib and Letrozole | Phase 2 | Breast Cancer | - | - |
BYL719 | Phase 2 | Colorectal Cancer | - | - |
MYO-029 | Phase 2 | Becker Muscular Dystrophy | - | - |
Temodar and Irinotecan | Phase 2 | Glioblastoma | - | - |
MET097 Injection | Phase 2 | Obesity in Diabetes | - | - |
SRA-333 | Phase 2 | Alzheimer's Disease | - | - |
CI-1040 | Phase 2 | Colorectal Neoplasms | - | - |
Varenicline Adaptive Protocol | Phase 2 | Nicotine Dependence | - | - |
PF-04950615 (RN316) | Phase 2 | Hypercholesterolemia | - | - |
PF-04360365 | Phase 2 | Alzheimer's Disease | - | - |
PF-06463922 | Phase 2 | ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC | - | - |
Sunitinib malate (SU011248) | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Gefitinib + Sunitinib | Phase 2 | Carcinoma, Renal Cell | - | - |
Pertuzumab/Trastuzumab | Phase 2 | Metastatic Breast Cancer With a Isolated Brain Progression | - | - |
PF-04383119 (RN624) | Phase 2 | Low Back Pain | - | - |
PF-06865571 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
PF-04217329 - Middle Dose | Phase 2 | Primary Open-Angle Glaucoma | - | - |
COVID-19
6 drugs in this indication
Major Depressive Disorder
2 drugs in this indication
Obesity
2 drugs in this indication
alopecia areata, nonscarring alopecia (NSV)
1 drug in this indication
nonsegmental vitiligo
1 drug in this indication
Overweight
1 drug in this indication
Renal Transplantation
1 drug in this indication
alopecia areata, non-scarring alopecia (NSV)
1 drug in this indication
Vitiligo
1 drug in this indication
Bladder cancer
1 drug in this indication
weight-loss
1 drug in this indication
oncology
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
1 drug in this indication
rare skin disease
1 drug in this indication
Diabetes Mellitus
1 drug in this indication
HRR-altered metastatic castration-resistant prostate cancer
1 drug in this indication
COVID-19 prevention (XFG variant)
1 drug in this indication
Lymphoma, B-Cell
1 drug in this indication
vaccine
1 drug in this indication
front-line maintenance breast cancer
1 drug in this indication
relapsed/refractory multiple myeloma
1 drug in this indication
pediatric pneumonia
1 drug in this indication
Cisplatin-eligible muscle-invasive bladder cancer (MIBC)
1 drug in this indication
Lyme disease
1 drug in this indication
BRAF V600–mutant melanoma
1 drug in this indication
Muscle invasive bladder cancer (in combination with enfortumab vedotin-ejfv)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in PFIZER's drug pipeline?→
CatalystAlert tracks 810 drug candidates in PFIZER's (PFE) pipeline across Phase 3, Phase 2. Its lead program is Ritlecitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PFIZER's next FDA catalyst?→
PFIZER's (PFE) next tracked catalyst is a Phase 3 readout expected Q4 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PFE biotech catalysts?→
Add PFE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PFIZER's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
